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Abstract 
Type 2 diabetes is a devastating disease affecting hundreds of millions worldwide. 
Lipid accumulation in peripheral non-adipose tissues is a major driver of insulin 
resistance, a central pathophysiological defect of this disease. Plasma free fatty acids 
(FFA), derived from adipose tissue lipolysis, are an important source of the intra-
cellular lipid pools. Hence, adipose tissue antilipolysis may be an approach for 
reversing peripheral tissue lipid overload and the down-stream negative consequences, 
including insulin resistance. 
Nicotinic acid (NiAc) is a potent inhibitor of adipose lipolysis, acutely reducing 
plasma FFA concentrations. However, a major FFA rebound occurs upon abrupt NiAc 
washout and sustained exposures are associated with tolerance development, with FFA 
returning to pre-dose levels. A key principle of this work was the use of precisely defi-
ned plasma NiAc exposure profiles, produced using a programmable, implantable mini-
pump. Metabolic consequences of NiAc-induced FFA lowering were assessed in a tran-
slationally relevant preclinical model of the metabolic syndrome, the obese Zucker rat. 
A feedback turnover model adequately described acute FFA responses to NiAc. This 
model aided in designing a gradual NiAc termination protocol which minimized FFA 
rebound. The strategy of around-the-clock exposure failed to deliver sustained FFA 
lowering, due to tolerance development. By contrast, an intermittent strategy succeeded 
in preserving acute FFA lowering and insulin sensitizing effects. A more complex 
model was required in order to capture the development of complete tolerance in 
response to sustained NiAc exposure. Further experiments revealed that NiAc timed to 
feeding decreased triglycerides in liver and heart and reduced plasma fructosamine. 
During an oral glucose tolerance test, plasma FFA levels were reduced with amelio-
ration of hyperglycemia and hypertriglyceridemia. By contrast, NiAc timed to fasting 
did not reduce tissue lipids, ameliorate glucose intolerance or dyslipidemia. 
In conclusion, the NiAc exposure profile has a major influence on metabolic control.  
A macro-pharmacologic approach succeed in identifying a rational NiAc delivery pro-
file that suppressed rebound and tolerance and profoundly improved metabolic control 
in obese Zucker rats. The work shows the power of a multi-disciplinary drug discovery 
approach, using a comprehensive understanding of the relationship between pharmaco-
kinetics and pharmacodynamics combined with knowledge of metabolic physiology. 
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1 Introduction 
Disturbances in metabolism underlie several of the most debilitating and costly 
diseases of the industrialized world, type 2 diabetes (T2D) and cardiovascular 
diseases (Inzucchi et al., 2012; Mozaffarian et al., 2016).  In health, metabo-
lism is dynamic and modulated by multiple redundant systems (Frayn, 2009). 
In this context, the standard pharmacological approach of activating a target 
mechanism around-the-clock often fail because of time dependent loss of drug 
efficacy and rebound above pre-dose levels. This thesis explores the idea that a 
more comprehensive understanding of the relationship between pharmaco-
kinetics (PK) and pharmacodynamics (PD) combined with knowledge of the 
physiologic regulation of metabolism (i.e. considering the effect of key bio-
markers)  can be used to mitigate these barriers enabling invention of new 
pharmacotherapies. This was done in the multi-disciplinary drug discovery 
environment at AstraZeneca R&D Gothenburg. The results in this thesis 
exemplify the value of comprehensive physiologic and PK/PD understanding 
by applying this approach to an ancient drug, nicotinic acid (NiAc). Thus, a 
well-defined exposure profile, including shape, extent and timing of drug inter-
vention, was designed sequentially across several studies. This resulted in 
suppression of tolerance and rebound and most importantly, profound improve-
ments of the metabolic profile of a preclinical disease-model. 
1.1 Type 2 diabetes 
During the past few decades there has been a global trend in lifestyle changes, 
dominated by an increased intake of high-fat/energy-dense foods, together with 
a sedentary lifestyle. These factors have caused the worldwide prevalence of 
obesity to escalate dramatically. In 2014, over 600 million people were obese, 
representing 13% of the global adult population (World Health Organization, 
Fact sheet N 311, 2015). Obesity is highly associated with T2D (Kahn et al., 
2006), a devastating disease currently affecting ~380 million people world-
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wide, and predicted to increase to almost 600 million by 2035 (Guariguata et 
al., 2014). T2D is associated with several risk factors, including increased risk 
of heart disease and stroke (Morrish et al., 2001), kidney failure (Alwan, 2011) 
and an overall increased risk of premature mortality (Roglic & Unwin, 2010). 
The major hallmark of the pathophysiology of T2D is insulin resistance, a 
situation where cells no longer respond appropriately to insulin. Although 
several mechanisms may trigger insulin resistance, it occurs primarily at the 
level of so-called insulin sensitive tissues such as liver, muscle and fat 
(Boucher et al., 2014). Genetic predisposition may be an important component 
in the development of T2D (Beck-Nielsen & Groop, 1994). However, insulin 
resistance emerges primarily as a consequence of over nutrition coupled to a 
sedentary lifestyle, resulting in severely disrupted fuel metabolism (Reaven, 
1995). Particularly pronounced is a perturbed lipid metabolism (McGarry, 
1992), fueled by an imbalance between lipid supply and oxidation at the tissue 
level (Flatt, 1988; Frayn, 2002; Eckel et al., 2005). This imbalance produces an 
elevated systemic FFA flux which results in peripheral lipid accumulation; i.e. 
lipid deposition in non-adipose tissues, such as, liver and skeletal muscle. 
Peripheral lipid accumulation has been shown to be a major driver of insulin 
resistance, nonalcoholic steatohepatitis (NASH) and dyslipidemia 
(Shulman, 2014; Lomonaco et al., 2016; Krauss, 2004). New pharmaco-
logical therapies are needed to decrease tissue lipid loading and thereby reverse 
the negative metabolic consequences. 
Insulin resistance is a prominent feature of both obesity and T2D (Kahn et 
al., 2006; Guilherme et al., 2008) and characterized by the failure of insulin to 
exert its normal functions. One important function is the insulin-induced fuel-
switch in skeletal muscle (Fig. 1): from predominant FFA oxidation during 
fasting to glucose oxidation following meal ingestion. In obese and insulin 
resistant people this fuel-switching is impaired, resulting in a state of metabolic 
inflexibility (Kelley et al., 1999). 
Over time, insulin resistance results in a progressively worsening hyper-
insulinemia, as the hypersecreting pancreatic β-cells tries to compensate for 
reduced insulin action in various tissues (Reaven, 1988). Control of fuel 
homeostasis is normally governed by insulin-stimulated glucose uptake into 
peripheral tissues and efficient suppression of lipolysis in adipose tissue 
(Frayn, 2009). Numerous metabolic abnormalities surface as a result of 
defective insulin action and secretion. This includes hyperglycemia, due to 
impaired insulin-stimulated glucose uptake into skeletal muscle (Kelley & 
Mandarino, 1990), paralleled by an elevated glucose production in the liver 
(DeFronzo et al., 1989). Furthermore, insulin resistance gives rise to an 
abnormal lipid metabolism, resulting in elevated levels of circulating lipids 
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(Mooradian, 2009). These chronic increases in plasma glucose and lipid 
concentrations can further damage insulin action and secretion, exacerbating 
the insulin resistant state (Muoio & Newgard, 2008). Obese and insulin 
resistant humans can, however, remain in this β-cell compensatory state for 
long periods of time without developing diabetes. Nonetheless, at some point a 
subset of these individuals will transition from an insulin resistant state to overt 
T2D (Weyer et al., 1999; Festa et al., 2006), brought about by β-cell failure 
(Kahn, 1998). 
 
Figure 1. Metabolic flexibility. The ability of skeletal muscle to switch between oxidizing 
glucose or fat is heavily related to insulin sensitivity, fitness and obesity status. During fasting 
conditions, insulin levels are normally low and in a lean individual there is high dependence on 
fat oxidation. In an obese, sedentary individual, however, there is less dependence on fat and a 
greater reliance on glucose oxidation. During insulin stimulated conditions, in skeletal muscle of 
a lean individual, insulin strongly suppresses fat oxidation and induces a high reliance upon 
glucose oxidation, whereas in skeletal muscle of an obese, sedentary individual, there is less 
stimulation of glucose oxidation by insulin and blunted suppression of fat oxidation. 
(Adapted from (Kelley et al., 1999)). 
Dyslipidemia is the primary cause for cardiovascular disease in T2D (Grundy 
et al., 1999). A vast body of evidence suggests that insulin resistance can be 
ascribed a central role in diabetic dyslipidemia with an increased FFA flux as a 
major contributing factor (Taskinen, 2003; Krauss & Siri, 2004; Solano & 
Goldberg, 2005; Chahil & Ginsberg, 2006). Dyslipidemia is characterized by 
three cardinal features, namely elevated plasma concentrations of triglycerides 
(TGs), reduced high-density lipoprotein-cholesterol (HDL) and perhaps most 
importantly an increased amount of low-density lipoprotein cholesterol (LDL) 
and changes in its composition (Howard, 1999); often termed the atherogenic 
lipoprotein phenotype (Austin et al., 1990). Hyperinsulinemia along with the 
elevated systemic FFA flux, promotes enhanced hepatic TG production, sub-
sequently causing an increased secretion of apolipoprotein B (ApoB) and very-
Suppressed glucose 
oxidation
Less suppression of 
glucose oxidation
Metabolically flexible Metabolically inflexible
Lean, aerobically fit individual Obese, aerobically unfit individual
Robust stimulation 
of glucose oxidation
Less stimulation of 
glucose oxidation
During insulin stimulated conditions
During fasting conditions
Robust preference 
for fat oxidation
in muscle
Blunted preference 
for fat oxidation
in muscle
Suppression of
fat oxidation
Blunted suppression 
of fat oxidation
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low-density lipoprotein cholesterol (VLDL) (Frayn et al., 2006). The ensuing 
TG and VLDL elevation worsens the lipoprotein phenotype. Specifically, HDL 
is reduced while small dense (sd)-LDL is increased (Mooradian, 2009). 
Circulating cholesteryl ester transfer protein (CETP) will, under these con-
ditions, catalyze the transfer of cholesteryl ester from HDL into VLDL while 
TG moves in the opposite direction. This results in cholesterol-rich VLDL 
remnants and TG-enriched, but cholesterol-depleted HDL (Lewis & Rader, 
2005; Mooradian et al., 2008); both of which are atherogenic (Ginsberg, 2002). 
A similar mechanism account for the increase in sdLDL particles; due to 
elevated VLDL, CETP facilitates exchange between LDL and VLDL, 
producing TG-enriched but cholesterol-depleted LDL. The TG-enriched LDL 
particle is subsequently hydrolyzed by hepatic lipase or lipoprotein lipase 
(Packard, 2003), leaving behind a lipid-depleted pro-atherogenic sdLDL 
particle (Lamarche et al., 1997). 
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized 
clinical condition in obesity and highly associated with insulin resistance and 
the pathogenesis of T2D (Dixon et al., 2001; Bugianesi et al., 2005). NAFLD 
describes a range of liver diseases but they all share a common patho-
physiology of abnormal intracellular retention of lipids (steatosis) in the liver 
(Angulo, 2002). However, the degree may range from isolated steatosis to non-
alcoholic steatohepatitis (NASH). Patients with NAFLD and T2D are at 
increased risk of developing more aggressive forms of liver disease, including 
NASH, advanced fibrosis, cirrhosis or liver cancer (Adams et al., 2010; Cusi, 
2009; Starley et al., 2010; Bugianesi et al., 2007). Although the exact mecha-
nisms that triggering NASH progression are not fully understood, insulin 
resistance at the level of adipose tissue is highly associated with the degree of 
liver disease (Lomonaco et al., 2016). Thus, lipotoxicity appears to be the 
likely culprit (Neuschwander‐Tetri, 2010; Cusi, 2012; Lomonaco et al., 2012).  
1.2 Mechanisms of lipid-overload induced insulin resistance 
The molecular mechanism by which lipids induce insulin resistance is not fully 
understood. However, a strong correlation exist between the intracellular lipid 
pool and insulin resistance (Krssak et al., 1999; Perseghin et al., 1999; Hwang 
et al., 2007; Korenblat et al., 2008; Magkos et al., 2012). Circulating lipids, 
including plasma FFAs and TGs are important sources of this lipid pool (Frayn 
et al., 2006). When insulin binds and activates the insulin receptor, signal 
transduction requires a coordinated relay of intracellular events. These events 
mostly involve phosphorylation or dephosphorylation of various proteins along 
the transduction pathway. In skeletal muscle, following activation of the 
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insulin receptor, the cascade initiates via phosphorylation of insulin receptor 
substrate 1 (IRS-1). When IRS-1 becomes phosphorylated on tyrosine residues 
it functions as a docking protein for other second messengers, e.g. 
phosphatidylinositol 3-kinase (PI3K). PI3K is activated upon binding to IRS-1 
and subsequently, via several additional signaling intermediaries, promotes 
glucose transporter type 4 (GLUT4) to translocate to the plasma membrane. 
The fusion of GLUT4 with the plasma membrane ultimately results in glucose 
uptake into the skeletal muscle (Berg et al., 2006; Youngren, 2007). In both 
rodent and human skeletal muscle, impaired insulin-stimulated phosphoryl-
ation of IRS-1 and PI3K activation, has been shown to occur following i.v. 
lipid infusions or high-fat diets. Diacylglycerol (DAG) activated protein kinase 
C, i.e. novel PKC (nPKC) was then found to cause a serine-threonine cascade, 
resulting in serine phosphorylation of IRS-1 which inhibits the insulin-
stimulated tyrosine phosphorylation of IRS-1. The theta isoform (PKCθ) is 
thought to be involved in lipid-induced insulin resistance in skeletal muscle 
(Perseghin et al., 1996; Schmitz-Peiffer et al., 1997a; Schmitz-Peiffer et al., 
1997b; Griffin et al., 1999; Dresner et al., 1999; Yu et al., 2002). 
Insulin has profound effects on carbohydrate and lipid homeostasis in the 
liver. It promotes anabolic pathways such as stimulation of glycogen synthesis, 
de novo lipogenesis (DNL) and synthesis of lipoproteins, while suppressing 
gluconeogenesis, glycogen breakdown and VLDL secretion (Exton & Park, 
1967; Scrutton & Utter, 1968; Madison, 1969; Sparks & Sparks, 1994; 
Hellerstein et al., 1996). Many of the effects that insulin mediate in the liver 
are regulated via gene transcription; promoting expression of lipogenic and 
glycolytic genes while suppressing transcription of gluconeogenic genes 
(O'Brien & Granner, 1996). An important mechanism that interferes with 
insulin signaling in the liver also involves DAG. In this tissue DAG activates 
another nPKC, namely PKC epsilon (PKCε). Upon DAG-activation, PKCε 
binds to the insulin receptor tyrosine kinases, which inactivates the receptor. 
Thus, subsequent phosphorylation and activation of down-stream transduction 
mediators fails. Two major pathways inactivated via this mechanism are 
glycogen synthase activity and insulin-stimulated inhibition of gluconeogenesis 
(Samuel et al., 2007; Hammond et al., 2005; Nagle et al., 2007). 
Insulin promotes DNL in the liver by activating the transcription factor 
sterol regulatory element-binding protein-1c (SREBP-1c), which increases 
transcription of genes essential for hepatic lipid biosynthesis (Brown & 
Goldstein, 1997; Horton et al., 2002). The newly formed TGs are then secreted 
into the circulation as VLDLs destined for storage in adipose tissue, or to be 
used as fuel in muscle. Whereas the pathway for gluconeogenesis in liver 
becomes insulin resistant, insulin sensitivity in the SREBP-1c pathway is 
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maintained (Shimomura et al., 2000; Ferré & Foufelle, 2007). The insulin 
resistant status forces the insulin producing pancreatic β-cell to hyper-secrete 
insulin in a futile attempt to maintain metabolic homeostasis. Thus, hyper-
insulinemia promotes an elevated activation of SREBP-1c and thereby an 
accelerated VLDL secretion and hepatic TG accumulation. FFA derived from 
this cycle contributes to an increased systemic FFA flux, worsening the insulin 
resistant state in muscle and adipose tissue. Consequently, insulin resistance 
severely disrupts metabolic regulation resulting in hyperglycemia, hyperinsu-
linemia, and hypertriglyceridemia (McGarry, 2002; Lann & LeRoith, 2007). 
1.3 Adipose tissue lipolysis 
The main role of adipose tissue is to store (as TG) and release (as FFA) energy. 
It is now recognized, however, that adipose tissue is more than just a lipid 
storage depot. In fact, several hormones and paracrine signaling molecules are 
secreted from adipocytes, establishing this tissue as an endocrine organ with an 
important role in metabolism (Frayn et al., 2006; Kershaw & Flier, 2004). 
During periods of food deprivation, the primary energy source comes from 
circulating plasma FFA, released from adipose tissue. The mechanism by 
which lipid-stores are mobilized from adipose tissue, i.e. lipolysis (Fig. 2), is 
mediated via cAMP-activated lipases, primarily hormone sensitive lipase 
(HSL) and adipocyte triglyceride lipase (ATGL). Upon their activation, TGs 
stored in intracellular lipid droplets are hydrolyzed into glycerol and FFA and 
subsequently released to the circulation (Sztalryd et al., 2003; Zimmermann et 
al., 2004). Hormones, e.g. catecholamines, can activate lipolysis in adipocytes 
in times of elevated energy demands, e.g. acute stress or prolonged intensive 
physical activity. Catecholamines interact with the β-adrenoceptor, a G-protein 
coupled receptor (GPCR or GPR), resulting in an increased adenylate cyclase 
(AC) activity and thus increased intracellular concentrations of cAMP; thereby 
activating the cAMP dependent protein kinase A (PKA). Subsequently, PKA 
phosphorylates, thus activate, HSL and ATGL (Collins & Surwit, 2001). 
Insulin exerts a powerful inhibitory effect on adipose tissue lipolysis (Large 
et al., 2004). During food deprivation, circulating insulin levels are low, with 
minimal insulin-induced inhibition of adipocyte FFA release. However, follo-
wing meal ingestion and the subsequent secretion of insulin, a rapid and robust 
inhibition of lipolysis occur (Frayn, 2002). Upon binding of insulin to the 
insulin receptor, downstream enzymes are phosphorylated, ultimately 
activating phosphodiesterase-3B (PDE-3B). PDE-3B is an enzyme that break-
down cAMP into AMP, resulting in less activation of HSL (predominantly) 
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and thus inhibition of lipolysis (Loten & Sneyd, 1970; Degerman et al., 1998; 
Wijkander et al., 1998). 
Several GPCRs are involved in regulating adipocyte lipolysis, e.g. GPR43, 
GPR81 and GPR109A (Ge et al., 2008; Sakurai et al., 2014; Offermanns, 
2014), via modulation of cAMP. These receptors all have an inhibitory effect 
on lipolysis (i.e. antilipolysis) with metabolites stemming from tissue fuel 
oxidation as their natural endogenous ligands. Their physiological role is 
thought to involve regulation of lipid-stores under various extreme metabolic 
situations (Lafontan & Langin, 2009). For example, the ketone body β-
hydroxybutyrate, a metabolite produced upon FFA oxidation, is the endo-
genous ligand for GPR109A (Taggart et al., 2005). Thus, under prolonged 
periods of starvation, β-hydroxybutyrate negatively regulates its own 
production and may thereby function as a homeostatic feedback regulator to 
prevent ketoacidosis. 
 
 
 
Figure 2. G-protein coupled receptor and insulin involvement in regulating adipose tissue 
lipolysis. Stimulatory effects from GPR109A agonism vs. inhibitory effects of β-adrenergic 
receptor agonism and insulin on adipocyte lipolysis: breakdown of TG to FFA and glycerol. Ade-
nylate cyclase (AC); protein kinase A (PKA); hormone sensitive lipase (HSL); adipocyte 
triglyceride lipase (ATGL); G-protein coupled receptors (GPR); phosphodiesterase-3B (PDE3B). 
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1.4 Nicotinic acid-induced antilipolysis 
Nicotinic acid (NiAc; or niacin) is an ancient drug with a clinical history of 
over six decades and was the first medication employed in clinical treatment of 
dyslipidemia. In 1955, Altschul and co-workers discovered that serum chol-
esterol levels were markedly reduced following large doses of NiAc (Altschul 
et al., 1955). It is now recognized that NiAc has a pluripotent, dose-dependent 
effect on lipids and plasma lipoproteins, including decreased TG, LDL-
cholesterol and lipoprotein(a) and increased HDL-cholesterol (Carlson, 2005).  
At therapeutic concentrations, NiAc functions as a GPR109A agonist, 
potently inhibiting adipose tissue lipolysis resulting in a rapid reduction in 
plasma FFA concentrations (Tunaru et al., 2003; Offermanns, 2006). Despite 
this acute effect, clinical dosing designed for dyslipidemia management has not 
been associated with improved glucose control. A possible explanation may be 
that prolonged NiAc exposure is associated with tolerance development, with 
return of FFA to pretreatment levels (Oh et al., 2011). Furthermore, during 
rapid NiAc washout a major FFA rebound is seen, overshooting pretreatment 
levels (Ahlström et al., 2011); a phenomenon also observed with oral dosing in 
humans (Carlson & Oro, 1962; Lauring et al., 2012). This may be one reason 
for the apparent worsening of glycemic control with NiAc (Aye et al., 2014; 
Blond et al., 2014; Koh et al., 2014; Hu et al., 2015; Ooi et al., 2015; El 
Khoury et al., 2016; Goldie et al., 2016). It should be remembered that the 
clinical NiAc dosing regimen has not been designed to lower FFA or reduce 
peripheral lipid accumulation, rather the goal has been to ameliorate dyslipid-
emia, via pathways possibly independent of the FFA lowering mechanism 
(Lauring et al., 2012). Thus, a better understanding of NiAc’s non-lipoprotein 
effects (i.e. FFA lowering) may help to define rational dosing strategies that 
lead to improvement in overall metabolic control via peripheral tissue lipid 
unloading.  
Another important consideration may be the currently used extended release 
dosing regimen; once daily at bedtime to minimize flush (NIASPAN®, 
Prescribing Information). FFA increases naturally in the fasting state and it has 
recently been suggested that bedtime dosing might limit NiAc efficacy by 
triggering powerful counterregulatory mechanisms (Guyton et al., 2015). It is 
not unreasonable that bedtime dosing might also be involved in the above 
mentioned glucose metabolic impairments. Furthermore, FFA lowering alone 
induces a major shift from whole body fat to carbohydrate oxidation, due to 
decreased substrate competition (Wang et al., 2000). Therefore, NiAc-induced 
antilipolysis given at the right time (i.e. in conjunction with carbohydrate 
containing food) may be an approach for improving glucose control. 
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1.5 The obese Zucker rat – a model of metabolic disease 
Experimental work in this thesis makes extensive use of the obese (fa/fa) 
Zucker rat. This is one of the most widely used animal models of the metabolic 
syndrome disease cluster: obesity, insulin resistance, moderate hyperglycemia, 
glucose intolerance, dyslipidemia, lipid intolerance and hepatic lipid accumu-
lation (Rohner-Jeanrenaud et al., 1986; Terrettaz et al., 1986; Oakes ND et al., 
2005; Wallenius et al., 2013). Not only does this model display key features of 
human disease but effects of antidiabetic and antidyslipidemic pharmaco-
therapies are predictive of responses in patients (Wallenius et al., 2013; Fager-
berg et al., 2005), (Oakes ND et al., 2005; Fagerberg et al., 2007), (Chaput et 
al., 2000; Abourbih et al., 2009), (Balkan et al., 1999; Iepsen et al., 2015). 
During cross-breeding of Sherman and Merck stock M rats a spontaneous 
fa-mutation was discovered (Zucker & Zucker, 1961). By ~5 weeks of age, 
animals with homozygous allele mutation (fa/fa) are noticeably obese and by 
14 weeks, on ad lib standard rodent chow, body composition of the obese 
Zucker rat is >40% fat (Zucker & Antoniades, 1972). The fa/fa mutation 
results in a non-functioning leptin receptor (Phillips et al., 1996). Leptin is a 
lipokine and thus secreted from adipose tissue, particularly in response to 
insulin. Although leptin has been shown to have widespread systemic effects, it 
is heavily involved in energy homeostasis. Following binding of leptin to its 
receptor in the hypothalamus it functions as a satiety factor, reducing the drive 
to eat (Ahima & Flier, 2000). Therefore, obese Zucker rats are hyper-phagic in 
nature with a disrupted normal nocturnal eating pattern resulting in an 
excessive energy intake causing overt obesity (Becker & Grinker, 1977). 
1.6 Quantitative approaches 
To aid the search for efficacious dosing regimens, quantitative models 
describing the dynamics of FFA in response to NiAc were employed. 
Quantitative pharmacology involves the temporal description of drug exposure 
and/or the drug-induced response (Holford, 1990; Levy, 1993; Mager et al., 
2003). Typically, modeling is a sequential endeavor starting with the temporal 
analysis of plasma drug concentration, followed by the drug-induced response 
modelled as a function of the plasma kinetic model, i.e. pharmacokinetic-
pharmacodynamic (PK/PD) modeling  (Gabrielsson & Weiner, 2006). 
Tolerance models are needed in order to capture the phenomenon of 
decreased response following constant or repeated drug exposure. In biological 
systems, sustained drug exposures often disturb homeostasis, which may 
invoke counterregulatory mechanisms, opposing the drug-induced effect. For a 
simple turnover model, the response may be described by a single equation 
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where the rate of turnover depend on the level of response (Fig. 3A). As the 
response reaches some physiological limit, a decrease in response will  occur 
(Yao et al., 2006; Peletier & Gabrielsson, 2009). In the pool/precursor toler-
ance models the response (R) originates from a physiological pool (P). Build-
up and loss of P is governed by its turnover rate  (kin) and fractional turnover 
rate (ktol), respectively, whereas R is produced and lost by ktol and its fractional 
turnover rate (kout) respectively (Fig. 3B). Thus, the mass of the pool serves as 
input for the response compartment (R) and can either be stimulated or 
inhibited by a drug function. If a given fraction of the pool is pushed into the 
response compartment, a positive effect area (AUCE) is produced. However, an 
equal fraction is now needed to refill the pool, in order to re-establish equilibri-
um. This refill produces a rebound area (AUCR) and results in the intrinsic 
function that AUCE = AUCR, which in biological systems are rare (Licko & 
Ekblad, 1992; Bauer & Fung, 1993; Sharma et al., 1998). A more flexible class 
of tolerance models are the moderator governed models. In these models, feed-
back is governed by an endogenous moderator (M), which counteracts changes 
in R. When drug-induced changes occur in R, simultaneous changes will also 
occur in M, which in turn affects the level of R negatively (Fig 3C). When the 
impact of M on R is slow, i.e. ktol<kout, the system has a tendency to overshoot, 
before settling at a pharmacodynamic steady state (Rss). A rapid drug removal 
in these systems will in turn produce a rebound, due to the slow counteracting 
effects of M. In this system AUCE ≠ AUCR (Wakelkamp et al., 1996; Zuideveld 
et al., 2001; Bundgaard et al., 2006; Gabrielsson & Peletier, 2007). 
 
Figure 3. Simulated response vs. time for three classes of tolerance models. Simple feedback 
on turnover rate A), pool/precursor model B) and negative feedback via moderator C). The 
measured effect is represented by R while P and M represent the precursor of response and an 
endogenous moderator, respectively. The kout and ktol are the 1st-order rate constants of production 
and loss of R and M, and loss of P. A drug may inhibit or stimulate a system via a drug function, 
represented by H(C) and grey bars depict length of exposure. AUCE and AUCR represent the 
positive effect area and the rebound area, respectively. The dashed horizontal line in A represent a 
physiological limit while the dashed curve the response in a system without tolerance. (Adapted 
from (Gabrielsson & Weiner, 2006)). 
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1.7 Problem formulation 
Available evidence suggest that a major driver of insulin resistance and 
metabolic disease is excessive accumulation of lipids in non-adipose tissues, 
including muscle and liver. An important source of these lipids is derived from 
circulating plasma FFA, released from adipose tissue via lipolysis. Therefore, a 
potential strategy for correcting metabolic disease is to suppress lipolysis and 
thereby reverse peripheral lipid accumulation. NiAc potently inhibits lipolysis 
acutely, however, sustained NiAc exposures result in tolerance development 
and major FFA rebound upon abrupt drug withdrawal. Novel pharmacological 
approaches are needed to define dosing strategies to mitigate these issues and 
durably maximize FFA lowering. 
Rather than focusing on the molecular or physiological mechanisms under-
lying rebound and tolerance, a macro-pharmacologic approach has been used. 
A key principle has been the use of rational and well defined NiAc exposures. 
Thus, studies were performed at therapeutically relevant NiAc exposures i.e. at 
NiAc concentrations sufficient but not excessive for suppression of FFA. 
Tailor-made, well defined exposure profiles were produced with a low degree 
of invasiveness using a programmable, implantable mini-pump. The physico-
chemical properties of NiAc were ideal for this purpose. Furthermore, the rapid 
plasma half-life of NiAc offers the freedom to realize virtually any desired 
exposure profile. The metabolic consequences of FFA lowering experiments 
were performed in a translationally relevant preclinical model, the obese 
Zucker rat. 
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2 Aims 
 
The overall aim of this thesis was to explore the idea that a more compre-
hensive understanding of the relationship between pharmacokinetics and 
pharmacodynamics, combined with knowledge of metabolism, can be used to 
mitigate challenges in drug discovery and thereby enable increased trans-
latability of preclinical findings and invention of new pharmacotherapies. 
Specifically, to find a NiAc delivery profile (shape and timing of exposure) 
that overcomes challenges such as tolerance and rebound in order to establish 
durable FFA lowering, sufficient to reverse peripheral lipid accumulation and 
improve insulin sensitivity in obese Zucker rats. 
Specific hypotheses tested in Papers I-IV were: 
I That a turnover model of NiAc-FFA captures experimental data from 
obese Zucker rats.  Apply the model to explore future dosing regimen 
designs. 
II That 1) continuous therapeutically relevant NiAc exposure delivers durable 
FFA lowering and 2) that intermittent (12 hr/day) NiAc exposure circum-
vents tolerance development and improves insulin sensitivity in conscious 
lean and obese rats. 
III That: 1) gradual vs. abrupt NiAc withdrawal attenuates FFA rebound; 2) 
NiAc applied during feeding, but not fasting, improves metabolic control. 
IV That a revised quantitative model, which alongside NiAc kinetics includes 
insulin dynamics and time-dependent tolerance development, improves 
model description of FFA dynamics.  
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3 Overview and progression of studies 
The results described in this thesis originate from in vivo experiments in lean 
and obese rats. An important goal of this thesis was to optimize NiAc-induced 
antilipolytic treatment to better metabolic control. An overview and pro-
gression of studies is summarized in Table 1. 
Table 1. Thesis overview, including main problem formulation, hypotheses, key findings, conclusions 
and drug discovery (Dx) implications. 
 Paper I Paper II Paper III Paper IV 
 Optimizing nicotinic acid delivery to better metabolic control 
Problem Quantitative tool for 
tolerance & rebound 
 
Retaining drug efficacy 
upon repeated dosing 
Address FFA rebound & 
further improve tolerance 
Improved quantitative 
model 
Hypotheses Model captures response in 
obese rats 
Intermittent dosing will  
-reduce tolerance 
-improve metabolic control 
 
Exposure timed to feeding 
with gradual washout will 
-reduce rebound & tolerance 
-improve metabolic control 
 
Inclusion of insulin, 
kinetics & tolerance 
improves description 
of FFA dynamics 
Design Feedback turnover model 
Obese rats 
Acute dosing 
Acute & repeated dosing 
Continuous vs. intermittent 
Lean & obese rats 
Repeated dosing 
Timed exposure food vs. fast 
Obese rats 
 
Meta-analysis of 
Paper I-III 
Key 
findings 
Model captures obese data 
Marked  & rapid tolerance 
Intermittent dosing 
-reduced tolerance 
-retained drug efficacy 
-acutely better insulin 
sensitivity 
 
Exposure timed to feeding 
-reduced rebound & 
tolerance 
-improved metabolic control 
Model captures 
-repeated 
-intermittent 
-gradual washout 
Insulin-FFA potency 
Conclusions Tolerance may reduce 
efficacy chronically 
 
Next step 
Repeated dosing for 
chronic disease 
Intermittent dosing retains 
efficacy 
 
Next step 
-Post-prandial dosing? 
-Rebound tackled by shape? 
Timing & shape essential for 
improved metabolic control 
 
Modeling requires 
drug & endogenous 
modulators 
 
Future encompasses 
timing & shape of 
exposure 
 
Drug Dx Importance of time-series 
Disease model 
Continuous vs. intermittent 
drug exposures 
Programmable, implantable 
mini-pump 
Time exposure to physiology 
Shape of exposure 
Meta-analysis 
Rank candidates 
Predict designs 
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4 Materials and methods 
4.1 Animals 
All experimental procedures were approved by the local Ethics Committee for 
Animal Experimentation (Gothenburg region, Sweden). Male Sprague Dawley 
(lean) and obese (fa/fa) Zucker rats (obese) were purchased from Charles River 
Laboratories (USA). Animals were housed in an Association for Assessment 
and Accreditation of Laboratory Animal Care accredited facility with climate-
controlled room temperature of 20-22°C and relative humidity of 40-60% with 
a 12 hr light-dark cycle (lights on at 06:00). For Paper III animals only, light-
dark cycle was offset by 1 hr (lights on at 07:00). The animals were housed in 
groups of 5 and given free access to standard rodent chow (R70, Laktamin AB, 
Stockholm, Sweden) and regular tap water. 
4.2 Nicotinic acid exposure selection and formulation 
A key aspect throughout the study designs was to achieve therapeutically 
relevant plasma NiAc concentrations in the rat. Based on the acute relationship 
between plasma NiAc concentration and FFA lowering obtained in Paper I, 
therapeutic plasma NiAc concentrations of ~1 µM were established. For intra-
venous (i.v.) infusions, NiAc (pyridine-3-carboxylic acid, Sigma-Aldrich, St. 
Louis, MO, USA), was dissolved in sterile saline. For subcutaneous (s.c.) in-
fusions, NiAc was dissolved in sterile water and adjusted to physiological pH 
using sodium hydroxide. The final concentrations of the s.c. NiAc dosing solu-
tions ranged between ~0.35-1.0 M. Vehicle for control animals consisted of 
saline at equimolar concentrations. Freshly prepared formulations were loaded 
into the infusion pump (see below) via a 0.2 µm sterile filter (Acrodisc®, Pall 
Corporation, Ann Arbor, MI, USA) just before pump implantation. 
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4.3 Study Protocols and surgical preparations 
Paper I 
Acute NiAc-induced changes in plasma FFA concentrations were explored 
after different rates and durations of intravenous NiAc infusions. The 
exposure-response relationships were determined and quantified on the basis of 
a turnover model with feedback mechanisms, and used together with the 
parameter estimates to detect differences between lean and obese animals 
(Ahlström, 2011; Tapani et al., 2014). 
Surgical preparations: Surgery was performed under isoflurane anesthesia, 
with body temperature maintained at 37°C. Catheters were placed in the left 
carotid artery for blood sampling and right external jugular vein for 
NiAc/saline infusion. Catheters were exteriorized at the nape of the neck and 
sealed. After surgery, rats were housed individually and allowed a minimum of 
5 days recovery before initiation of the experiments. 
Experimental protocols: In the morning of the acute experiment, in over-
night fasted rats, venous catheters were connected to an external infusion pump 
(CMA 100, Carnegie Medicin AB, Stockholm, Sweden). Lean and Obese 
animals were randomly allocated into 2 NiAc infusion groups: 20 µmol∙kg-1 
over 30 min or 51 µmol∙kg-1 over 300 min. Following adaptation, basal blood 
samples were collected prior to NiAc administration. After this, multiple 
samples were drawn over 100 min in the 30 min infusion groups, and over 500 
min in the 300 min infusion groups. Blood samples were briefly kept on ice 
until centrifuged and stored at -20°C pending plasma NiAc and FFA analysis. 
Paper II 
Paper II included three studies. In Study I, the ability of an intermittent (12 
hr/day) vs. continuous (24 hr/day) NiAc exposure to suppress FFA levels were 
compared in lean and obese rats. In Study II whole body insulin sensitivity was 
assessed in obese rats following acute, continuous or intermittent NiAc 
exposure. In Study III, effects of alternating NiAc exposures on adipose tissue 
gene expression, and TG content in liver was assessed. 
Surgical preparations: Surgery was performed under isoflurane anesthesia, 
with body temperature maintained at 37°C. For NiAc/saline administration, a 
programmable mini-pump (iPrecio® SMP200 Micro Infusion Pump, Primetech 
Corporation, Tokyo, Japan) was implanted subcutaneously, via a dorsal skin 
incision. To allow blood sampling from animals in Study I, a catheter was 
placed in the right jugular vein. Animals were then housed individually and 
allowed 3 days of recovery before start of the pre-programmed pump infusion. 
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Experimental protocols: Lean and obese animals were divided into 3 dose 
groups and NiAc was given acutely (NiAc naïve) or following 5 days with 
either continuous (Cont. NiAc) or intermittent (Inter. NiAc) administration. 
Each dose group was matched with corresponding saline infused controls. 
NiAc infusions were given subcutaneously at 170 nmol∙min-1∙kg-1. On the last 
treatment day, an overnight fast was initiated (food removed at 24:00) and 
animals entered into one out of the three terminal acute experiments: Study I, 
Study II or Study III. 
Study I: Jugular catheters were connected to a swivel system and animals 
were left to adapt (3-4 hr) before blood sampling was initiated. Basal samples 
were taken in the 60 min period prior to NiAc/saline infusion (note that, in the 
Cont. NiAc groups, infusion pumps were on throughout this sampling period). 
Multiple blood samples were then collected under 8 hr, including a 5 hr 
NiAc/saline infusion period followed by a 3 hr washout period. Blood samples 
were briefly kept on ice until centrifugation and storage at -20ºC pending 
plasma analysis of NiAc, FFA, glucose and insulin. 
Study II: Whole body insulin sensitivity was assessed in anesthetized obese 
Zucker rats using hyperinsulinemic-isoglycemic clamps (for acute surgery pre-
parations, please see Paper I). Following stabilization, 2-3 basal blood samples 
were taken (with no NiAc/saline infusions in any group except Cont. NiAc). 
NiAc/saline was then i.v.-infused until end of experiment. After 60 min of 
NiAc/saline infusion, human insulin was infused at a constant rate based on 
estimated lean body mass, lbm (Oakes ND et al., 2005) at 60 
pmol∙kglbm-1∙min-1.  Target plasma glucose level for the clamp was determined 
for each animal to be equal to its own basal level (isoglycemia). Plasma 
glucose was clamped with a variable rate i.v. infusion of 20% (w:v) glucose. 
Steady state, in both plasma glucose level and glucose infusion rate (GIR), was 
generally achieved within 90 min of clamp start. Blood samples were collected 
throughout, centrifuged immediately and stored at -20ºC pending analysis of 
plasma FFA and insulin concentrations. 
Study III: After 5 days of continuous or intermittent NiAc/saline treatment, 
animals were anesthetized with isoflurane and tissues (liver and epididymal 
adipose tissue) were dissected, snap frozen in liquid nitrogen and stored 
at -80°C pending analysis of adipose tissue mRNA and liver TG content. 
Paper III 
Paper III included two studies. Study I was performed in anesthetized obese 
Zucker rats to address the issue of FFA rebound during NiAc withdrawal. 
Acute metabolic responses to either rapid (NiAc-Off) or gradual (NiAc-Stp-
Dwn) NiAc withdrawal were assessed under basal fasting or glucose infused 
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conditions. The results of Study I were used to select the NiAc delivery profile 
deployed in Study II (protocols and results for Study I can be found in Paper 
III). In Study II, metabolic responses of fasting-period vs. feeding-period NiAc 
exposure was compared. Obese Zucker rats, with food freely available during 
nighttime only (to entrain defined periods of feeding and fasting in these 
hyper-phagic animals), were treated for 5 days with NiAc (NiAc Day vs. NiAc 
Night). Acute experiments were then performed in the conscious state and 
metabolic control was assessed using an oral glucose tolerance test (OGTT). 
Surgical preparations: Surgery was performed under isoflurane anesthesia 
and body temperature maintained at 37°C. For NiAc/saline administration, a 
programmable mini-pump was used, as described above. A catheter was placed 
in the right jugular vein. Animals were housed individually until study 
completion, with a 3 day recovery before treatment start. 
Experimental protocol: For the Study I experimental protocol the reader is 
referred to Paper III. Study II: During 5 days of treatment, food was freely 
available during the 12 hr dark period only (lights on at 07:00). A daily NiAc 
exposure profile, with gradual step-wise decline, was timed either to day (NiAc 
Day group) or night (NiAc Night group) including a 12 hr drug holiday period. 
Daily NiAc dosing profiles commenced at 06:00 for NiAc Day and at 18:00 for 
NiAc Night, given as an 8.5 hr constant infusion at 170 nmol∙min-1∙kg-1 
followed by a 3.5 hr step-down protocol. All NiAc protocols were matched 
with saline infused controls. In the morning of day 5, the jugular catheter was 
connected to a swivel system. Following adaptation, blood sampling was 
initiated at 13:00. Corresponding to the timing of breaking the fast (19:00), 
animals received an oral glucose tolerance test (OGTT, 4.1 g∙kglbm-1, 8.2 
mL∙kglbm-1). Blood samples were centrifuged and plasma stored at -80ºC 
pending analysis for NiAc, FFA, glucose, insulin, fructosamine and TG. 
Following the last blood sample, animals were anesthetized with isoflurane and 
tissues (liver, heart and epididymal adipose tissue) were dissected and snap 
frozen in liquid nitrogen and stored at -80°C pending TG and mRNA analysis. 
Paper IV overview 
A more physiologically based FFA model was developed. The FFA dynamics 
are driven by both NiAc pharmacokinetics and the endogenous insulin 
dynamics. A nonlinear mixed-effects approach was applied to capture both 
population and individual behaviors using pooled data from several studies. 
Meta-analysis data: The developed models were challenged using data 
from Paper II (Study I) and Paper III (Study I, Glu- groups only). In addition, a 
group of lean animals were included, given 12 hr s.c. NiAc infusions followed 
by either abrupt or gradual switch-off (n=5/group, with corresponding saline 
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infused controls). A NiAc naïve group was also included (lean and obese, 
n=4-5/group, with corresponding controls) given a 1 hr constant i.v. NiAc 
infusion followed by either abrupt (Off 1 hr) or gradual switch-off (Stp-Dwn 1 
hr). A summary of data included in meta-analysis is given in Table 2. 
Table 2. Paper IV study data (number of saline infused controls are given in parenthesis) 
State Route Pre-treat. (hr) Acute inf. (hr) Protocol/group n Lean n Obese 
Conscious  s.c. 0 5 NiAc naïve 7 (2) 7 (5) 
Conscious s.c. 120 5 Cont. NiAc 6 (2) 8 (2) 
Conscious s.c. 120 5 Inter. NiAc 6 (2) 8 (3) 
Anesthetized i.v. 0 1 Off 1 hr 4 (3) 5 (3) 
Anesthetized i.v. 0 1 [+3.5 stp-dwn] Stp-Dwn 1 hr 5 (2) 5 (2) 
Anesthetized s.c. 0 12 Off 12 hr 5 (2) 4 (2) 
Anesthetized s.c. 0 12 [+3.5 stp-dwn] Stp-Dwn 12 hr 5 (3) 4 (3) 
Subcutaneous (s.c.); intravenous (i.v.) 
4.4 Analytical methods 
Plasma concentrations of FFA (Wako Chemicals, Germany), glucose (Horiba 
ABX, France), TG (Roche Diagnostics, Germany), fructosamine (Horiba ABX, 
France), as well as liver and heart TG content, following isopropanol extraction 
(Horiba ABX, France) were determined by enzymatic colorimetric methods 
using an ABX Pentra 400 (Horiba ABX Diagnostics, Kyoto, Japan). Plasma 
glucose in Paper II was measured using a portable blood glucose monitoring 
device (ACCU-CHEK® Compact Plus, Roche Diagnostics Indianapolis, 
Indiana, USA). Obese rat plasma insulin was analyzed by radioimmunoassay 
(RI-13K Rat Insulin RIA kit, Merck Millipore, Germany while lean rat plasma 
insulin concentrations were determined using a colorimetric ELISA kit (Ultra 
Sensitive Rat Insulin ELISA Kit, Crystal Chem INC, Downers Grove, IL, 
USA). The ELISA was used for lean rats to minimize blood sample volume 
(only 5 µL plasma required vs. ~50 µL plasma for RIA). The RIA was used for 
the obese rats because high lipid levels in the plasma of these animals interfere 
with the ELISA but not the RIA measurement. Because of the hyperinsulin-
emia in the obese animals only 5 µL of plasma was required. For Lean rat 
plasma (with low lipid levels) the absolute insulin measurement are equivalent 
for the RIA and ELISA assays (in house analysis). For plasma samples 
collected during the glucose clamp study (Paper II, Study II), total (rat + 
human) insulin was determined using the rat RIA and human insulin was deter-
mined by a species specific RIA (human insulin specific RIA kit, Millipore). 
Plasma NiAc concentrations were analyzed using LC-MS/MS with a hydro-
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philic interaction liquid chromatography (HILIC) approach, separated on a 50 
x 2.1 mm Biobasic AX column, with 5 μm particles (Thermo Hypersil-Key-
stone, Runcorn, Cheshire, UK). Analytical assays are summarized in Table 3. 
Area under the concentration-time curves (AUC) for plasma NiAc, FFA, 
insulin, glucose and TG were calculated by trapezoidal approximation, using 
GraphPad Prism 6.01 (GraphPad Software Inc., La Jolla, CA, USA). Lean 
body mass (lbm) was estimated from body weight as previously described 
(Oakes ND et al., 2005).  
RNA was extracted from liver and epididymal adipose tissue (EAT) and 
isolated according to the manufacturer’s instructions, using RNeasy® Mini Kit 
(Qiagend AB, Solna, Sweden). cDNA was reverse transcribed using a high 
capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, 
USA). Differences in gene expression was determined using a QuantStudio™ 
7 Flex Real-Time PCR System (Applied Biosystems). Please see Paper II and 
Paper III for primer sequences or TaqMan assay IDs. 
 
Table 3. Summary of analytical methods used for plasma and tissue biomarkers 
Biomarker Assay principle Manufacturer LLOQ 
Intra-assay 
(CV%) 
Inter-assay 
(CV%) 
FFA Colorimetric method Wako Chemicals 0.01 mM ≤1 ≤5 
Fructosamine Colorimetric method Horiba, ABX 13 µM ≤2 ≤4 
Glucose Gluco-meter Roche 0.6 mM ≤3 ≤5 
Glucose Colorimetric method Horiba, ABX 0.1 mM ≤1 ≤2 
Insulin (Lean) ELISA Crystal Chem 0.02 nM ≤10 ≤10 
Insulin (Obese) RIA Millipore 0.02 nM ≤5 ≤10 
NiAc LC-MS/MS Sciex API 5500 1-6 nM ≤10 ≤10 
Plasma TG Colorimetric method Roche/Hitachi 0.05 mM ≤1 ≤2 
Tissue TG aColorimetric method Horiba, ABX 0.08 mM ≤3 ≤2 
Enzyme-linked immunosorbent assay (ELISA); Radioimmuno-assay (RIA); Lower limit of 
quantification (LLOQ); aIsopropanol extraction. 
 
Statistics: In Paper II-III, statistical significance of post-hoc comparisons were 
evaluated based on 1-way ANOVA, adjusted for multiple comparisons, 
performed using GraphPad Prism 6.01 (GraphPad Software Inc., La Jolla, CA, 
USA). Comparisons between groups for repeatedly measured variables were 
based on AUC estimates. P<0.05 was considered statistically significant. 
Throughout, results are reported as mean ± standard error of the mean (SEM). 
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4.5 Numerical methods 
Paper I 
NiAc-induced inhibition of FFA release was described by I(Cp) and given by 
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where Cp, Imax, IC50 and denote the NiAc concentration in plasma, maximum 
drug-induced inhibitory effect, NiAc’s potency on FFA release and the Hill 
coefficient, respectively. 
The feedback of the Paper I model (Fig. 4A) is governed by a moderator 
(M), distributed over 8 transit compartments. M1 inhibits the release of FFA 
while M8 stimulates FFA plasma clearance. The moderator assumes to capture 
all endogenous FFA modulators, including insulin. The moderator is affected 
by FFA (R) via a 1st-order build-up of M (ktol·R), with a transit time of 1/ktol. 
Following FFA lowering, production of moderator will be reduced with a 
subsequent decrease in M1. With FFA formation inversely proportional to the 
moderator, raised to the power of p (M1
p), FFA will increase when M1 de-
creases. The signal transduction will eventually propagate through the mode-
rator compartments, causing the level of moderator in M8 to fall, reducing the 
loss of FFA. The concentrations of R and M1-8 will eventually equilibrate. 
Lipoprotein lipase can hydrolyze TG into FFA in the capillaries, and thus not 
affected by NiAc. This was initially incorporated as a zero-order production 
term kcap in the modeling of the obese rats. The FFA (R) dynamics are given by  
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where M1 and M8 are described above, kin is the turnover rate, p the 
amplification factor, I(Cp) the inhibitory drug mechanism function, kcap the 
lipoprotein lipase dependent FFA formation, and kout the fractional turnover 
rate of R. The turnover of the moderators are given by: 
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A more in depth description of the model is available in Paper I. 
34 
 
Figure 4. Diagrams of Paper I (A) and Paper IV (B) models. Solid and dashed lines represent 
flow and control, respectively. (1) NiAc inhibits insulin secretion. (2) Insulin have feedback 
mechanisms that inhibits its own turnover and (3) stimulates its own fractional turnover. Both (4) 
NiAc and (5) insulin inhibits FFA turnover. In Paper IV, (6) FFA have a single feedback 
mechanism, inhibiting its own turnover, while in the Paper I model, FFA were modelled using an 
(7) additional feedback mechanism which stimulates its fractional turnover. 
Paper IV 
The model developed in Paper IV is schematically described in Fig. 4B. For in 
depth description of the NiAc disposition model please see Paper IV. 
Insulin turnover model 
Insulin (I) dynamics were described by a feedback model and given by  
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with initial condition I(0)=I0 and M1I(0)=M2I(0)=M0I=I0. M1I and M2I is the 
first and second moderator, respectively. kinI and koutI represent insulin’s 
turnover rate and fractional turnover rate, respectively, and ktolI the moderators 
fractional turnover rate. NiAc’s inhibitory function on insulin, HNI(Cp), is given 
by 
NiAc
FFA
NiAc
FFA
1 2
3
4
5
6
4
6
7
InputInput
Insulin
Flux
Control
(A) Paper I model (B) Paper IV model
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where Cp is the plasma NiAc concentration , IC50NI the drug potency, and n the 
Hill coefficient. ENI(NI) represents the drug efficacy, which is dependent on the 
concentration in a hypothetical NiAc action compartment (NI), given by 
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where ImaxNI is the initial efficacy in a NiAc-naïve system, NIss=Cpss and thus 
the steady-state plasma NiAc concentration, and SNI the long-term NiAc 
sensitivity on insulin. The dynamics of NI, is given by 
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where kNI is the 1st-order rate constant of the NiAc action compartment, with 
initial condition NI(0)=Cp(0). To capture individual variations, random effects 
were incorporated. To determine which parameters that were allowed to vary 
between individuals, an a priori sensitivity analysis was performed and the 
four parameters that had the highest impact on the system output were chosen. 
Residual variation was modelled using an additive model. 
FFA turnover model 
The FFA (F) turnover model is given by 
 
    Fk
M
M
IHCHk
dt
dF
outF
F
F0
IFpNFinF     (8) 
 
where kinF and koutF represent the turnover and fractional turnover of FFA, 
respectively. HNF is the drug mechanism function representing NiAc’s 
inhibitory effect on FFA, while HIF represent insulins inhibitory effect on FFA 
and Cp the plasma NiAc concentration. MF is the moderator compartment and 
given by 
 
 FtolF
F MFk
dt
dM
      (9) 
 
with initial condition MF(0)=M0F=F0. ktolF represent the fractional turnover rate 
of the moderator compartment. HNF is given by 
 
   


pNF50
p
FNFpNF
CIC
C
NE1CH

   (10) 
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where IC50NF is NiAc’s potency on FFA lowering and γ is the Hill coefficient. 
NiAc’s efficacy on FFA is flexible and able to change over time and given by 
 
  







Fss
F
NFNFmaxFNF
N
N
S1INE    (11) 
 
where ImaxNF is the initial efficacy in a NiAc naïve system. SNF represent the 
long-term NiAc sensitivity on FFA, NF the concentration in a hypothetical 
NiAc action compartment acting on FFA and NFss the concentration in the 
action compartment at steady state. NF is described by  
 
 FpNFF NCk
dt
dN
      (12) 
 
with initial condition NF(0)=Cp(0). kNF is the 1st-order rate constant of the NiAc 
action compartment acting on FFA. The insulin mechanism function HIF is 
given by 
 
   
IIC
I
NE1CH
IF50
FIFpIF

     (13) 
 
where IC50IF represent insulins potency on FFA release and EIF its efficacy 
given by 
  







Fss
F
IFIFmaxFIF
N
N
S1INE     (14) 
where ImaxIF represent the initial efficacy in a NiAc naïve system. SNF represent 
the long-term insulin sensitivity on FFA. 
Random effects were based on an a priori sensitivity analysis (as described 
for the insulin model) and residual variation was modelled using an additive 
model. 
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5 Results 
5.1 Paper I 
NiAc disposition: NiAc infusions at 170 nmol∙min-1∙kg-1 resulted in plasma 
concentrations of ~1 µM in both lean and obese rats, with a tendency of 
slightly higher concentrations in obese vs. lean (Fig. 5A). NiAc disposition 
parameters are available and covered in detail in Paper I. 
 
Figure 5. Plasma concentration-time profiles of NiAc (A) and FFA (B), in lean (dotted lines) and 
obese (solid lines) during and after 300 min infusion of 51 µmol∙kg-1 NiAc (black) or saline 
(grey) administration. 
NiAc-induced changes in FFA response: In Lean rats, plasma FFA 
decreased rapidly to a lower physiological limit of ~0.055 mM. In Obese, 
however, the FFA reduction was slower with no apparent plateau level, 
indicating a reduced NiAc efficacy in obese vs. lean. During ongoing NiAc 
infusion (0-300 min), pronounced tolerance development was observed (Fig. 
5B). Following NiAc cessation, the return of FFA to baseline was slower in 
obese vs. lean rats, with FFA rebound being less pronounced.  
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Figure 6. Typical model fits of plasma FFA concentration-time data in obese Zucker rats after 
300 min infusion of 51 µmol∙kg-1 NiAc. Black circles are observed data while solid and dotted 
lines depict individual and population fits, respectively. 
Model prediction: Predicted and experimental data were consistent, and the 
model captured the elevated FFA baseline concentrations, slowly developing 
tolerance and the small oscillatory FFA rebound following 300 min infusions 
in obese rats. Representative observed and population predictions of changes in 
FFA concentrations in Obese are shown in Fig. 6. 
Concentration-response relationship: The equilibrium NiAc concentration-
FFA response relationships of lean and obese rats were simulated using the 
final parameter estimates (available in Paper I). It can be seen from Fig. 7 that 
the steady state FFA concentration (RSS) was noticeably higher in obese vs. 
lean, over the entire range of simulated concentrations. There was a sigmoid 
relationship between the simulated steady state concentration of NiAc and FFA 
in lean, with decreasing FFA as NiAc concentrations increased from ~0.02 to 
0.5 µM. In Obese, FFA concentrations decreased progressively with increasing 
NiAc concentrations, with no evident plateau. Thus for obese, the curve was 
more shallow and shifted upwards vs. lean. 
 
Figure 7. Simulated steady state plasma NiAc vs. predicted FFA concentrations at equilibrium 
(RSS) for obese (solid line) and lean (dotted line) rats. Differences between lean and obese rats are 
given at (a) low, (b) therapeutic and (c) high NiAc concentrations. 
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5.2 Paper II 
Nicotinic acid exposure: The target steady state plasma NiAc concentration of 
~1 µM was successfully achieved in both lean and obese groups (Fig. 8). 
 
Figure 8. Plasma NiAc concentration in lean (left) and obese (right) with NiAc 
(170 nmol∙min-1∙kg-1) given acutely (NiAc naïve, n=7/group) or following 5 days continuous 
(Cont. NiAc, lean n=4, obese n=8) or intermittent (Inter. NiAc, lean n=4, obese n=9) or 11 days 
intermittent (Inter. NiAc D11, obese n=4) dosing. Data presented as mean ± SEM. Bottom black 
bars represent the Basal, Infusion and Post Infusion Periods, respectively. 
Plasma FFA: In both lean and obese rats, NiAc-induced FFA lowering was 
completely lost in the Cont. NiAc group after 5 days of continuous, 
uninterrupted NiAc infusion (Fig. 9). In contrast, intermittent NiAc dosing 
succeeded in retaining significant FFA lowering during the Infusion Period vs. 
corresponding saline control (lean: P<0.05; obese: P<0.001, Paper II Fig. 4A). 
Unlike lean, in the obese Inter. NiAc group, there was some loss of the extent 
of FFA lowering vs. NiAc naïve (P<0.001, Paper II Fig. 4A). Importantly, an 
additional group of obese animals, studied following 11 days of intermittent 
NiAc (Inter. NiAc D11), showed no further development of tolerance (Inter. 
NiAc Day 11 vs. Inter. NiAc, P>0.05, Paper II Fig. 4A). During the Post 
Infusion Period, FFA rebound of various magnitude was observed in both lean 
and obese. Interestingly, the lean, but not obese, Cont. NiAc group also 
exhibited a rebound vs. saline (Fig. 9; P<0.001, Paper II Fig 4B), consistent 
with a previous study (Oh et al., 2011). Remarkably, in the lean animals over 
the whole 8 hr observation period, none of the NiAc protocols reduced total 
FFA AUC (Paper II, Fig. 4C). In obese rats, total 8hr FFA AUC lowering was 
achieved only in the NiAc naïve group (-36%, P<0.001 vs. saline control, 
Paper II Fig. 4C), Thus, intermittent NiAc dosing retained FFA lowering 
efficacy, but the FFA rebound following NiAc cessation tends to cancel the net 
FFA lowering effect. In the obese Cont. NiAc group, total FFA AUC was 
actually increased vs. saline control (P<0.05, Paper II Fig 4C). 
 
L e a n
T im e  (h r s )
N
iA
c
 (
µ
M
)
-2 0 2 4 6 8
0 .0 0 1
0 .0 1
0 .1
1
1 0
In fu s io n
P e r io d
P o s t  I n f u s io n
P e r io d
B a s a l
P e r io d
O b e s e
T im e  (h r s )
N
iA
c
 (
µ
M
)
-2 0 2 4 6 8
0 .0 0 1
0 .0 1
0 .1
1
1 0
N iA c  n a ïv e
C o n t. N iA c
In te r . N iA c
In te r . N iA c  D 1 1
40 
 
Figure 9. NiAc-induced plasma FFA responses in lean (left) and obese (right) following infusion 
of saline (Lean n=5, Obese n=12) or NiAc given either acutely (NiAc naïve) or following 5 days 
continuous (Cont. NiAc), intermittent (Inter. NiAc) or 11 days intermittent (Inter. NiAc D11) 
dosing. Data presented as mean ± SEM. Bottom black bars represent the Basal, Infusion and Post 
Infusion Periods, respectively. 
Insulin and glucose: Compared to corresponding saline infused controls, 
plasma insulin concentrations were reduced during the Infusion Period (Fig. 
10A-B) in lean NiAc naïve, Obese NiAc naïve and Obese Inter. NiAc (P<0.05, 
Paper II Fig. 6A). This occurred in absence of change in glycemia (Fig. 10C-D, 
P>0.05, Paper II Fig. 7A), suggesting an improvement in insulin sensitivity. 
 
Figure 10. Plasma insulin (A, B), and glucose (C, D) in lean (left column) and obese (right 
column) after NiAc/saline infusion given acutely or after 5 days continuous (Cont. NiAc) or inter-
mittent (Inter. NiAc) or 11 days intermittent (Inter. NiAc D11) dosing. Data presented as mean ± 
SEM. Bottom black bars represent the Basal, Infusion and Post Infusion Periods, respectively. 
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The rebound phenomenon was not just restricted to FFA. Insulin rebounds 
were observed in all NiAc dosed groups (Fig 18A-B) with the exception of 
Obese Cont. NiAc (Fig. 10B). As for FFA (described above), reduction in 
insulin AUC achieved during the Infusion Period tended to be cancelled during 
the Post Infusion Period, with the result that total 8hr insulin AUC is similar in 
all NiAc groups compared to respective saline control groups (Paper II Fig. 
6C). NiAc succeeded in moderately lowering blood glucose in the Obese NiAc 
naïve group (-11%, P<0.001, Paper II Fig. 7C), although this effect was not 
maintained with either intermittent or continuous NiAc dosing. 
Effects of alternating NiAc exposures on whole body insulin sensitivity: In 
the NiAc naïve group, glucose infusion rate (GIR) was markedly increased 
compared to saline infused controls (+92%, P<0.01). Importantly, the Inter. 
NiAc group also had an elevated GIR (+71%, P<0.05), similar in magnitude to 
the NiAc naïve group (P>0.05), compatible with a sustained insulin sensiti-
zation of the intermittent dosing approach. In stark contrast, upon continuous 
dosing, this effect was completely lost (P>0.05 vs. saline control, Fig. 11). 
 
 
 
 
 
 
Figure 11. Glucose infusion rate (GIR) at 
clamp steady state in obese Zucker rats. 
+P<0.05, ++P<0.01 vs. saline; ¥¥P<0.01 vs. 
Cont. NiAc. Data presented as mean ± SEM 
(n=6/group). 
 
 
 
 
NiAc induced changes in adipose tissue gene expression: Overall there was 
no evidence that a coordinated alteration in expression of genes was 
responsible for the tolerance development in either lean or obese rats (Paper II 
Table 3). 
Liver triglyceride (TG) content: In both lean and obese rats, NiAc (either 
intermittent or continuous exposure) had no significant impact on liver TG 
content (Paper II Table 4). 
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5.3 Paper III 
Nicotinic acid exposure: Target plasma NiAc concentrations were similar at ~1 
µM in both NiAc infused groups (Fig. 12A). By design, following pre-
programmed initiation of the step-down protocol at 14:30, plasma NiAc levels 
declined gradually in the Day group, taking ~3.5 hr to reach acute in vivo IC50 
for FFA lowering, ~0.070 µM (vs. 1.5 hr for abrupt termination Paper III Fig. 
2A). NiAc exposure was much higher during the 13:00-19:00 time period in 
the Day vs. Night groups. Conversely, during the OGTT period (19:00-21:00), 
NiAc exposure was much higher in the Night vs. Day group. 
 
Figure 12. Study II, plasma NiAc concentrations on day 5 of programmed NiAc delivery, 
given either during fasting (NiAc Day) or feeding (NiAc Night) in obese Zucker rats 
†††P<0.001 vs. NiAc Day. Data presented as mean ± SEM (n=8/group). 
Plasma FFA: As expected, in the Saline group the oral glucose load at 
19:00, reduced FFA levels (Fig. 13A). Strikingly, Day vs. Night dosing had 
completely opposite effects on FFA levels during the OGTT. In the Day group 
FFA was increased (P<0.05), whereas in the Night group it was reduced 
(P<0.01) vs. Saline (Fig. 13B). Dosing NiAc to feeding resulted in 60% lower 
plasma FFA vs. daytime dosing (P<0.001).  
 
Figure 13. Study II, plasma FFA responses after 5 days of programmed NiAc delivery, given 
either during fasting (NiAc Day) or feeding (NiAc Night) in obese Zucker rats. *P<0.05, 
**P<0.01, vs. Saline; †††P<0.001 vs. NiAc Day. Data presented as mean ± SEM (n=8/group). 
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Plasma glucose: NiAc Night improved glycemia in the 13:00-19:00 fasting 
period vs. Day and Saline groups (P<0.01, Fig. 14B). Following glucose 
loading (OGTT), the Night group displayed a remarkable improvement in 
glucose control (19:00-21:00, Fig. 14A), with markedly improved glucose 
control vs. Day and Saline groups (-27% P<0.001, -22% P<0.01, respectively, 
Fig. 14B). After achieving peak levels at 15 min post glucose load, glucose 
levels were restored much more rapidly to baseline vs. Day and Saline groups. 
 
Figure 14. Study II, plasma glucose responses after 5 days of programmed NiAc delivery, 
given either during fasting (NiAc Day) or feeding (NiAc Night) in obese Zucker rats. 
Corresponding to the timing of breaking the fast (19:00) animals received an oral glucose load 
(4.1 g∙kglbm-1). **P<0.01, vs. Saline; ††P<0.01, †††P<0.001 vs. NiAc Day. Data presented as mean ± 
SEM (n=8/group). 
Plasma insulin: During both the fasting and OGTT periods, NiAc timed to 
feeding exhibited lower insulin vs. NiAc Day (P<0.05, Fig. 15B). These data 
indicate that NiAc timed to feeding: 1) decreases insulin secretory burden vs. 
daytime dosing and 2) enhances insulin sensitivity, given the reduced fasting 
and OGTT levels of glycemia. 
 
Figure 15. Study II, plasma insulin responses after 5 days of programmed NiAc delivery, 
given either during fasting (NiAc Day) or feeding (NiAc Night) in obese Zucker rats. †P<0.05 
vs. NiAc Day. Data presented as mean ± SEM (n=8/group). 
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Plasma triglyceride (TG): During the 13:00-19:00 fasting period there was a 
tendency for the NiAc groups to exhibit lower plasma TG levels vs. Saline. 
During the OGTT period, NiAc dosed to feeding decreased TG AUC(19:00-21:00) 
vs. Saline (P<0.05 Fig. 16B). This was not observed with dosing to fasting 
 
Figure 16. Study II, plasma TG responses after 5 days of programmed NiAc delivery, given 
either during fasting (NiAc Day) or feeding (NiAc Night) in obese Zucker rats. *P<0.05 vs. 
Saline. Data presented as mean ± SEM (n=8/group). 
Liver and heart triglyceride (TG): Five days of programmed NiAc 
delivery, applied during nighttime feeding periods, dramatically reduced 
liver TG content vs. Saline and Day groups (P<0.01, and P<0.05, respec-
tively). This was not the case with NiAc during daytime fasting periods, 
which had no effect on liver TG content vs. Saline. Heart TG content was 
markedly reduced in the Night vs. Day and Saline groups (P<0.001, 
P<0.05, respectively). In complete contrast, heart TG content was increased 
in the Day vs. Saline group (P<0.05, Fig. 17). Cardiac TG content across 
the groups paralleled the FFA exposures immediately prior to tissue 
collection (FFA AUC(19:00-21:00)): linear regression r2 = 0.67, P<0.0001. 
 
Figure 17 Study II, (left) liver and (right) heart triglyceride (TG) content following 5 days of 
programmed NiAc delivery, given either during fasting (NiAc Day) or feeding (NiAc Night) 
in obese Zucker rats. *P<0.05, **P<0.01 vs. Saline; †P<0.05, †††P<0.001 vs. NiAc Day. Data 
presented as mean ± SEM (n=8/group). 
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De novo lipogenesis (DNL) gene expression: Quantitative RT-PCR was 
conducted in liver samples to assess a potential involvement of a down-
regulation in the DNL pathway in the observed reduction in liver TG in the 
Night group. Indeed, expression of two important master regulator genes, 
carbohydrate-responsive element-binding protein (ChREBP) and sterol regula-
tory element binding protein-1c (SREBP-1c), as well as four of their regulated 
genes directly involved in DNL, acetyl-CoA carboxylase 1 (ACC1), fatty acid 
synthase (FAS), fatty acid elongase 6 (Elovl6) and stearoyl-CoA desaturase-1 
(SCD1) were downregulated compared to the saline control group. By contrast, 
hepatic expression of genes in the Day group were unchanged relative to the 
controls. The other major site of DNL in the body is adipose tissue. By contrast 
with the results in the liver, there was no significant treatment associated 
regulation of DNL genes in epididymal adipose tissue (Fig. 18).  
 
Figure 18. Study II, mRNA expression analysis of genes involved in de novo lipogenesis 
(DNL) in liver (top) and epididymal adipose tissue (bottom). Tissues were harvested following 
5 days of programmed NiAc delivery, given either during fasting (NiAc Day) or feeding (NiAc 
Night) in obese Zucker rats. *P<0.05, **P<0.01 vs. Saline; ††P<0.01 vs. NiAc Day. Data is 
normalized to housekeeping gene ribosomal protein large P0 (RPLP0) and presented as mean ± 
SEM (n=8/group). 
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5.4 Paper IV 
The models were evaluated using visual predictive check (VPC) plots (Post et 
al., 2008; Bergstrand et al., 2011) and presented as the model predicted median 
individual with corresponding 90% prediction intervals, superimposed on 
observed experimental data (Fig. 19). 
Pharmacokinetic model: The VPC plots capture the NiAc exposure-time 
course for all NiAc protocols (Fig. 7 & 8 Paper IV). The 90% prediction 
intervals covers all but 32 out of the 650 data points (~95%). Figure 19 (left 
column) shows 3 representative model predictions of plasma NiAc concen-
trations in lean rats, following different durations of NiAc infusions. The aim 
of modeling NiAc concentration-time data was to obtain individually fitted 
time-courses to co-drive the FFA concentration-time data. NiAc disposition 
parameter were estimated with relatively high precision (Table 2, Paper IV).   
 
Figure 19. Population model fits of plasma concentrations of NiAc (left column), insulin 
(mid column) and FFA (right column) in lean rats. NiAc was given as a 5 hr s.c. infusion 
either acutely (NiAc naïve, top row) or following 5 days intermittent (Inter. NiAc, mid row) or 
continuous (Cont. NiAc, bottom row) NiAc dosing. Solid lines represent the predicted median 
individual and the grey area contained within the dashed lines represent the 90% prediction 
intervals. Open circles are the experimental observations. 
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Insulin model: The aim of modeling insulin concentration-time data was to 
obtain individually fitted time-courses to co-drive the FFA dynamics. The VPC 
plots shows that the model captures the general insulin-time course adequately 
with the predicted median individual following the course of the median data 
points (for all data see Fig. 7 & 8, Paper IV). For some NiAc protocols the 
model under-predicts the behavior of the mean (Fig. 7K & N and Fig. 8K & T, 
Paper IV). Overall the model was able to capture the main insulin observations 
in both lean and obese rats, including NiAc-induced insulin suppression, 
adaptation following long-term infusions and rebound upon infusion cessation.  
The 90% prediction intervals covered all but 144 of the 1834 data points 
(approximately 92%). Figure 19 (mid column) shows 3 representative model 
predictions of plasma insulin concentrations in lean rats, following different 
durations of NiAc infusions. Parameter estimates for the insulin model were 
determined with relatively high precision (Table 2, Paper IV).  
FFA model: In lean rats, the VPC plots shows that the model captures the 
general FFA time-course adequately, with the predicted median individual foll-
owing the course of the median data points (for all lean data see Fig. 7, Paper 
IV). Due to Paper IV being a work still in progress, at present, obese FFA 
parameter estimates has not yet been attained and precision in lean FFA 
parameter estimates are under assessment. However, in lean, the developed 
model structure allows for a system to be fully responsive to NiAc and insulin 
acutely (Fig. 19C) and following intermittent NiAc dosing (Fig. 19F). Over 
time tolerance develops with FFA returning towards baseline (Fig. 19I). 
 
Figure 20. Population model fits of plasma FFA concentrations in anesthetized lean rats. 
NiAc was infused for 1 hr (A-B) or 12 hr (C-D), with abrupt (left column, NiAc Off) or gradual 
switch-off (right column, Stp-Dwn). Solid lines represent predicted median individual, grey area 
represent the 90% prediction intervals. Open circles are experimental observations. 
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The future potential and flexibility of the model structure to capture FFA dyna-
mics following various NiAc infusion regimens are shown in Fig. 20. The 
model adequately captures the FFA responses in anesthetized lean rats follo-
wing a constant rate NiAc infusion for either 1 hr or 12 hr followed by either 
abrupt termination (Fig. 20A & 20C) or gradual withdrawal (Fig 20B & 20D). 
The 90% prediction intervals cover essentially all experimental observations. 
The ability of the FFA model to capture experimental data, was more 
evident on individual level, compared to the population median individual fits. 
The FFA model adequately captured individual FFA responses following 
acute, intermittent and continuous NiAc exposure (Fig. 21). Thus, inclusion of 
insulin along-side NiAc to co-drive the FFA response resulted in a model that 
captures FFA dynamics following a wide range of NiAc exposure durations, 
from 1 hr out to 5 days.  
 
Figure 21. Representative model fits of individual plasma FFA concentrations. NiAc was 
given as a 5 hr s.c. infusion either acutely (NiAc naïve) or following 5 days intermittent (Inter. 
NiAc) or continuous (Cont. NiAc) NiAc dosing. Solid and dashed lines represents the individual 
and population fits, respectively. The grey area contained within the dotted lines represent the 
90% population prediction intervals. Open circles are the individual experimental observations. 
In this thesis Paper IV is in manuscript form and hence analysis and results are 
preliminary. The final parameter estimates, as well as estimate uncertainties, 
will upon completion add further knowledge and validity to the currently 
presented results. 
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6 Discussion 
6.1 Background 
This thesis explores the idea that a more comprehensive understanding of the 
relationship between pharmacokinetics (PK) and pharmacodynamics (PD) 
combined with knowledge of the physiologic regulation of metabolism (i.e. 
considering effects of key biomarkers) can be used to mitigate challenges such 
as tolerance and rebound phenomena, enabling invention of new drug 
therapies. 
Available evidence suggest that a major driver of insulin resistance and 
metabolic disease is excessive accumulation of lipids in non-adipose tissues, 
including muscle and liver (Shulman, 2014; Lomonaco et al., 2016; Krauss, 
2004). An important source of these lipids is derived from circulating plasma 
FFA, released from adipose tissue via lipolysis (Frayn et al., 2006). Therefore, 
a potential strategy for correcting metabolic disease is to suppress lipolysis and 
thereby reverse peripheral lipid accumulation. 
NiAc potently inhibits lipolysis acutely, however, sustained NiAc exposures 
result in tolerance development and major FFA rebound upon abrupt drug 
withdrawal (Oh et al., 2011; Carlson & Oro, 1962; Vega et al., 2005). This 
may be one reason for the apparent worsening of glycemic control with NiAc 
(Aye et al., 2014; Blond et al., 2014; Koh et al., 2014; Hu et al., 2015; Ooi et 
al., 2015; El Khoury et al., 2016; Goldie et al., 2016). Another important factor 
may be the currently used extended release dosing regimen; once daily at 
bedtime to minimize flush (NIASPAN®, Prescribing Information). FFA 
increases in the fasting state and it has recently been suggested that bedtime 
dosing might limit NiAc efficacy by triggering powerful counterregulatory 
mechanisms (Guyton et al., 2015). It is not unreasonable that bedtime dosing 
might also be involved in the above mentioned glucose metabolic impairments. 
Moreover, an insulin-NiAc synergy on antilipolysis (Paper II) would favor 
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mealtime over bedtime dosing. Novel pharmacological approaches are needed 
to define dosing strategies to mitigate challenges such as tolerance and rebound 
in order to maximize FFA lowering. 
In the present thesis, rather than focusing on the molecular mechanisms 
underlying rebound and tolerance, a macro-pharmacologic approach was used. 
A key principle has been the use of well-defined therapeutically relevant NiAc 
exposures, i.e. concentrations sufficient, but not excessive, for suppression of 
FFA in rats. Tailor-made, exposure profiles were produced with a low degree 
of invasiveness, using a programmable, implantable mini-pump. The physico-
chemical properties of NiAc were ideal for this purpose. Furthermore, the rapid 
plasma half-life of NiAc offers the freedom to realize virtually any desired 
exposure profile. The metabolic consequences of FFA lowering experiments 
were performed in a translationally relevant preclinical model, the obese 
Zucker rat. 
6.2 Paper I 
The main purpose of Paper I was to assess and quantify differences in NiAc-
induced FFA responses between lean Sprague Dawley and obese Zucker rats. 
Following acute NiAc administration, plasma FFA responses in obese rats 
were applied to an existing quantitative model. This feedback model was 
originally developed (Ahlström et al., 2011) and challenged (Ahlström et al., 
2013) to describe NiAc-induced changes in FFA concentrations in lean rats. 
Given that lean rats often serve as a primary screening model during preclinical 
drug discovery, it is important to determine how drug-induced responses 
translates to an animal model of disease. Furthermore, a quantitative model that 
adequately describes a drug-induced response may have predictive value 
beyond the data from which it was developed. Thus, challenged and validated 
quantitative models may then serve as a valuable tool when designing new 
studies. 
While NiAc effectively decreases plasma FFA concentrations to ~10% of 
baseline levels in lean (Ahlström et al., 2013), corresponding infusion rate in 
obese produced a reduction to ~30% of baseline levels. Compared to lean, the 
onset of response was slower in obese rats, with more pronounced tolerance 
development during the period of constant NiAc exposure. Although an FFA 
rebound was observed following NiAc cessation, the magnitude was sub-
stantially less in obese compared to lean rats. 
Insulins regulatory impact on FFA was modelled as a series of transit 
compartments, with the moderator in the first and last compartment 
representing a rapid (Stralfors et al., 1984; Frayn et al., 1994) and slow (Frayn 
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et al., 1994; Sadur & Eckel, 1982) regulation, respectively. Although the 
pharmacodynamic characteristics of the obese rats in Paper I differed from lean 
rats, the feedback model managed to successfully described the observed 
NiAc-induced FFA responses in obese rats. This included the elevated basal 
FFA level, pronounced tolerance development and the diminished rebound.  
Generally, obese parameters were estimated with high precision, with no 
apparent residual plot correlations. Compared to lean, R0, kin and p were 
increased by 44, 41 and 78 %, respectively, while kout and  were reduced by 
64 and 84 %. The ktol and IC50 were similar in both rat strains. 
The concentration-response relationships at equilibrium differed between 
lean and obese rats, with obese displaying an upward shift and a shallower 
shaped curve, compared to lean. The extent of such shifts are important, as 
they demonstrate the impact of disease at equilibrium and, if ignored, may lead 
to erroneous dose predictions and consequently poorly designed studies.  
In summary, the feedback model captured the acute experimental data cons-
istently and NiAc-induced FFA responses was found to differ between lean and 
obese rats. The pronounced tolerance development, observed during constant 
drug exposure, suggests that 24 hr drug coverage may substantially reduce 
NiAc efficacy. Future studies beyond the acute dosing situation are needed to 
explore whether an optimized NiAc treatment regimen, e.g. intermittent 
dosing, could achieve durable FFA lowering. 
6.3 Paper II 
The standard pharmacological approach of engaging the target mechanism 
(GPR109A activation) for 24 hr/day fails in the case of NiAc, as prolonged 
exposure induces tolerance development, with FFA returning to pretreatment 
levels (Oh et al., 2011). In paper II, it was hypothesized that by interspacing 
daily NiAc exposures with drug holidays, tolerance development might be 
circumvented and NiAc-induced FFA lowering efficacy would be retained. If 
true, non-adipose tissues (primarily liver and muscle) would then receive a 
reduced 24 hr average FFA exposure, resulting in reversed peripheral lipid 
accumulation and thereby improved metabolic control. This hypothesis was 
tested by comparing FFA lowering in lean Sprague Dawley and obese Zucker 
rats in response to a 5 hr NiAc infusion, in either NiAc-naïve (acute dosing) 
animals, or after 5 days of continuous (24 hr/day) or intermittent (12 hr/day) 
NiAc exposure. To assess treatment effects on insulin sensitivity, hyper-
insulinemic-isoglycemic clamps were performed in obese Zucker rats. 
Additionally, the impact of the alternative dosing regimens on expression of 
selected adipose tissue genes involved in FFA mobilization were examined.  
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The intermittent drug holiday approach succeeded in retaining the ability of 
a therapeutically relevant NiAc exposure to induce FFA lowering. In lean rats, 
following intermittent (12 hr on/12 hr off) infusions for 5 days, the acute NiAc-
induced FFA suppression was completely preserved. While in the obese rats 
there was a partial loss of FFA lowering efficacy, following 5 days intermittent 
dosing, importantly, this did not appear to be progressive with similar FFA 
lowering at 11 vs. 5 days. By contrast, continuous NiAc infusion for 5 days 
resulted in complete return of FFA to pre-treatment levels, consistent with 
previous findings (Oh et al., 2011). 
Markedly improved insulin sensitivity was seen in association with NiAc 
induced FFA lowering, either in NiAc naïve or previously intermittently dosed 
obese Zucker rats. Acute suppression of circulating FFA levels by NiAc in the 
obese animals was associated with reduced fasting hyperinsulinemia. Reduced 
insulin secretion might be explained by direct effects on the islets of either 
NiAc (Li et al., 2011) or the fall in FFA level (Dobbins et al., 1998).  
However, if the effect was only to decrease insulin secretion then levels of 
glycemia should have increased, which was not the case. Reduced fasting 
insulinemia in association with normoglycemia suggests instead that NiAc 
enhanced whole body insulin sensitivity. Indeed, this was confirmed by the 
elevated GIRs needed to maintain isoglycemia during the hyperinsulinemic 
clamps. In contrast to the intermittent group, continuous NiAc exposure did not 
enhance whole body insulin action. 
Tissue lipid loading is determined both by acute circulating lipid levels 
(plasma FFA and TG) and the intracellular lipid stores. The ability of plasma 
FFA lowering alone, to significantly impact on total tissue fatty acid utilization 
has been clearly demonstrated by work showing that acute NiAc 
administration, in the fasting state, induces a major shift from whole body fat 
to carbohydrate oxidation, in association with the suppression of plasma FFA 
(Wang et al., 2000). The intension was to reverse lipid overload, not just by 
reducing acute circulating FFA, but also by lowering tissue lipids via a 
reduction of net (24 hr average) FFA exposure. However, the AUC analysis 
suggests that the FFA rebound upon abrupt NiAc withdrawal, is of a magnitude 
sufficient to cancel the acute NiAc-induced FFA lowering in the intermittently 
dosed groups, despite the fact that this presumably only occurred once per day. 
Failure to lower net FFA exposure was also indicated by the lack of liver TG 
lowering. This may well explain why the enhancement in GIR was similar in 
the NiAc naïve and previously intermittently dosed groups. 
Changes in adipose tissue gene expression of genes involved in liberating 
vs. storing FFAs, was not associated with the loss of FFA lowering during 
prolonged NiAc infusion. Previous studies in rats and mice have reported 
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substantial downregulation of PDE-3B, which the authors argued could be an 
important mechanism responsible for the return of FFA to pretreatment levels 
during prolonged NiAc exposure (Oh et al., 2011; Heemskerk et al., 2014). An 
explanation for the discrepancy between the present study and the previous 
work has not been found, although one possible cause might be that in the 
present study substantially lower NiAc doses were used, ~1/10th of those used 
in the earlier studies. 
The rebound phenomena are different in lean vs. obese. To our knowledge, 
this is the first study to assess the detailed, time dependent response of plasma 
insulin and glucose in response to sudden NiAc withdrawal. In all cases where 
there was a FFA rebound, this was associated with an insulin rebound, with a 
particularly pronounced response in the obese NiAc naïve animals. This pheno-
menon may be the result of the well-known potentiation of glucose stimulated 
insulin secretion by long chain FFAs (Dobbins et al., 1998). However, the 
surprisingly modest glycemic reductions in response to the insulin rebound, 
suggest that the complete explanation is likely more complex. Indeed, Vega et 
al. (Vega et al., 2005) suggested that NiAc induced FFA lowering might 
trigger a counterregulatory response, perhaps to defend substrate supply, and 
NiAc has been shown to significantly alter levels of a number of hormones 
including glucagon and growth hormone (Quabbe HJ et al., 1983). The 
mechanism of the loss of FFA lowering, in response to continuous NiAc 
exposure appears to be different in lean and obese animals. Thus in the lean 
animals, sudden withdrawal of NiAc after 5 days of uninterrupted exposure, 
induced a marked FFA rebound. This is consistent with the interpretation of Oh 
et al. (Oh et al., 2011), that the return of FFA to pre-infusion levels represents 
the net effect of preserved NiAc action in the presence of an enhanced basal 
rate of lipolysis. By contrast, in obese Zuckers there was absolutely no 
evidence of FFA rebound indicating that lipolysis had become completely 
tolerant to NiAc i.e. complete tachyphylaxis.   
Further refinements to NiAc dosing might achieve greater lipid lowering 
and insulin sensitization. To this end, fine-tuning of the infusion protocol 
and/or optimal timing of NiAc administration relative to food intake might 
mitigate these issue. Thus a programmed, more gradual decline in NiAc 
concentrations to terminate each infusion period might help to minimize the 
rebound. Alternatively, FFA rebound might be minimized if NiAc withdrawal 
is timed to occur in association with feeding/insulin administration. This might 
especially be the case if the proposal that FFA rebound involves a counter-
regulatory response (Vega et al., 2005) to defend substrate supply is correct. 
In summary, the intermittent NiAc dosing strategy succeeded in retaining 
FFA lowering and improving insulin sensitivity in obese Zucker rats. While 
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these data suggest that FFA lowering is sufficient to improve insulin 
sensitivity, further refinements of the NiAc dosing regimen should be explored 
to more profoundly reverse lipid-overload induced insulin resistance. 
6.4 Paper III 
Further refinements to the NiAc dosing regimen were made in Paper III. To 
fully realize the potential of NiAc-induced antilipolysis on improving 
metabolic control, net FFA lowering must be achieved. To this end, the FFA 
rebound issue must be solved. The magnitude of the FFA rebound appears to 
be highly associated with NiAc’s relatively short plasma half-life, thus if the 
washout period could be extended the FFA rebound issue might be mitigated 
(Ahlström et al., 2013). Furthermore, timing of NiAc exposure with respect to 
feeding or fasting periods was not considered in Paper II. This is an important 
aspect since antilipolysis during fasting periods may invoke a more powerful 
counterregulatory response to defend the supply of the predominant oxidative 
fuel (Guyton et al., 2015; Vega et al., 2005). Hence NiAc exposure during 
feeding, which in rodents coincide with the nighttime period, might deliver 
most benefit to both glucose and FFA control. In Paper III these hypotheses 
were tested by comparing 5 days of fasting (daytime) vs. feeding (nighttime) 
NiAc exposure in obese Zucker rats. To entrain defined periods of feeding in 
these hyper-phagic animals, food was available during the nighttime periods 
only. In a pre-study (Study I, Paper III), the effects of abrupt vs. gradual NiAc 
withdrawal in either the basal fasted or glucose infused situation were 
compared. The rational was to assess which combination that delivered the 
minimal FFA rebound. This combination would then be deployed in the fasting 
vs. feeding study. Following the 5 day treatment period, metabolic control was 
assessed by an oral glucose tolerance test (OGTT) followed by tissue sampling 
to evaluate lipid unloading and potential effects on gene expression. 
The timing and shape of the intermittent NiAc exposure profile have a 
major impact on metabolic control. Specifically, timing a well-defined NiAc 
exposure to feeding periods, terminated by an engineered gradual washout 
profile, results in marked improvements in the metabolic phenotype of the 
obese Zucker rat. These include plasma FFA and TG lowering, as well as, 
improved glycemic and lipid control. Perhaps most significantly, however, is 
the substantial peripheral tissue lipid unloading, implying a long term, 
fundamental improvement of metabolic control. Importantly, these effects are 
achieved without any measurable change in food intake or body weight (Fig. 3, 
Paper III). By contrast, these improvements are not observed when timing 
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NiAc exposure to fasting periods, with a 12 hr time-shifted but otherwise 
identical NiAc administration protocol. 
Post-prandial NiAc exposure likely enhanced the FFA lowering during the 
treatment period, given the relative hyperinsulinemia associated with this state. 
Although the anti-lipolytic effects of both NiAc and insulin are mediated via 
adipocyte cAMP lowering, their combined effects are theoretically synergistic 
since NiAc, via GPR109A agonism, decreases cAMP formation (Tunaru et al., 
2003) while insulin increases cAMP breakdown, through enhanced phospho-
diesterase-3B (PDE-3B) activity (DiPilato et al., 2015). An insulin-NiAc 
synergy is not just a theoretical possibility, but was in fact seen in Paper II 
during the hyperinsulinemic clamps. The observed post-prandial FFA lowering 
is likely the primary mechanism driving the metabolic improvements resulting 
from dosing NiAc with feeding. Reduced FFA supply to the tissues should 
lower substrate competition with glucose (Wang et al., 2000) and improve 
insulin sensitivity (Paper II) just when it is needed the most, i.e. during the 
influx of dietary carbohydrate in the post-prandial phase, resulting in reduced 
post-prandial hyperglycemia and hyperinsulinemia. 
Evidence that NiAc timed to feeding succeeded in reducing 24 hr average 
FFA levels is provided by the tissue TG data. In the heart, TG stores parallel 
the FFA exposure during the period leading up to tissue collection, likely 
reflecting the quantitative dependence of this lipid pool on plasma FFA and its 
high turnover rate. Thus, the NiAc timed to feeding-induced reduction in FFA 
exposure during the OGTT is associated with a reduction in cardiac TG, in 
striking contrast to the opposite responses seen in the daytime dose group. This 
unloading of the much larger liver TG pool may result from both direct and 
indirect effects of the post-prandial FFA lowering. The latter from the longer 
term effects of repeated reductions in post-prandial hyperglycemia and hyper-
insulinemia leading to reduced hepatic de novo lipogenesis (DNL). This path-
way is heavily regulated via transcriptional control by glucose and insulin 
(Postic & Girard, 2008).  Strong evidence for reduced hepatic DNL with NiAc 
timed to feeding is provided by the observed downregulation of the master 
regulatory genes, ChREBP and SREBP-1c, as well as four of their regulated 
genes directly involved in DNL, namely ACC1, FAS, Elovl6 and SCD1. The 
absence of a significant change in adipose DNL genes suggests that excess 
dietary glucose is partitioned away from the liver and into adipose tissue. 
Hepatic TG lowering might be an important driver of the observed reduction in 
post-prandial hypertriglyceridemia, which would also tend to reduce ectopic 
lipid accumulation and its negative consequences (Shulman, 2014). 
In summary, the dosing regimen, in the context of a fixed daily dose, has a 
critical influence on whether or not NiAc improves metabolic control in the 
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obese Zucker rat. Specifically, Paper III demonstrate that timing a well-defined 
intermittent NiAc infusion protocol to feeding periods, is actually able to 
reverse ectopic lipid accumulation and improve lipid and glucose control. 
These data support the concept that antilipolysis, applied in conjunction with 
feeding, can be an effective means of reversing lipid overload induced insulin 
resistance and dyslipidemia. 
6.5  Paper IV 
A new model structure was implemented in order to capture the complete 
tolerance development following sustained NiAc exposures (observed in Paper 
II). The hypothesis was that a quantitative model built upon repeated dosing 
data more accurately would capture NiAc-induced FFA dynamics. NiAc has a 
major influence on insulin dynamics, with patterns resembling the FFA 
responses; acute reduction upon starting a NiAc infusion, tolerance 
development upon sustained NiAc exposures, with major rebound seen upon 
abrupt NiAc withdrawal (Paper II & III). Moreover, NiAc-induced FFA and 
insulin responses differed between lean and obese rats.  
Given the potent endogenous antilipolytic effects of insulin (Arner et al., 
1981), and the large dynamic changes in insulin in response to NiAc, the model 
was expanded to include insulin dynamics as a co-driver of the FFA response, 
alongside NiAc kinetics. Linking FFA to insulin dynamics gives an 
opportunity to quantitatively determine insulin potency on FFA dynamics. The 
derived model can then be used as a tool to further optimize NiAc delivery to 
maximize FFA lowering and improve metabolic control. 
The new model structure was needed in order to describe the rather unique 
transition of this system; from being fully sensitive to NiAc and insulin upon 
acute or intermittent dosing, into a system which at a later time point following 
sustained NiAc exposure, displays complete tolerance development. Interest-
ingly, the tolerance development on response to continuous NiAc exposure 
appear to have different temporal aspects in lean vs. obese. Following 5 days of 
uninterrupted NiAc exposure, both lean and obese rats displayed a return of 
FFA to pretreatment levels, despite ongoing NiAc infusions. However, in lean 
rats a FFA rebound was seen upon NiAc cessation, consistently with a previous 
study (Oh et al., 2011). In contrast, corresponding obese group did not produce 
a rebound upon NiAc cessation, indicating complete tolerance development. 
Thus, NiAc’s efficacy to suppress FFA changes over time appears to have 
different temporal aspects in lean vs. obese. To derive a mathematical model 
able to capture these observations a hypothetical NiAc action compartment was 
incorporated into the model. In this compartment, NiAc’s efficacy on 
57 
FFA/insulin is non-constant and allowed to change over time. This resulted in a 
model structure which was able to capture different degrees of NiAc efficacy 
with respect to time. 
To become clinically meaningful, durable NiAc-induced FFA lowering 
must be established. Specifically, the daily net FFA exposure (24 h FFA 
exposure) must be reduced in order to limit the FFA being supplied to the liver. 
Thus, both tolerance and rebound need to be contained. Given the NiAc-
induced FFA dynamics in the present data, clearly sustained NiAc exposures 
would not deliver this effect since a complete loss of efficacy occurs. In 
contrast, the intermittent dosing approach appears to contain tolerance 
development. However, at the end of the 12 h infusion, a major FFA rebound is 
seen, tending to cancel out the lowering achieved during the infusion periods. 
Whether there is an optimal length of exposure which would maximize the 
drug-induced effect while at the same time produce a minimal rebound, still 
needs to be explored. This is not a trivial task, not least due to the number of 
possible infusion profiles.  To this end, the predictive power of a quantitative 
model, as the one presented here, can reduce the infinite number of imaginable 
infusion protocols down to a few plausible candidates. 
Despite major changes in both insulin and FFA dynamics, plasma glucose 
concentrations remained remarkably stationary in the present study data (see 
paper II & Paper III, Glu- groups). Therefore, glucose was assumed to have 
minor influence on insulin and FFA dynamic seen in the present data. Hence, 
in order to reduce an already very complex system, an active decision was 
made to omit glucose dynamics in the present analysis. Given the remarkable 
impact of timing NiAc exposure to feeding vs. fasting (Paper III), future model 
generations will be extended to encompass glucose dynamics to further 
improve the predictive and translational value. 
In summary, in the present study we developed a novel NiAc-FFA model, 
linking insulin dynamics to the release of FFA and quantitatively assessed 
insulin’s potency and sensitivity on FFA dynamics. The current analysis is still 
in development and awaits the final FFA parameter estimates for obese rats, 
along with final FFA estimate uncertainties. Nonetheless, the model was found 
to have promising potential by displaying the ability to capture the FFA 
response time-courses following a variety of different NiAc infusion regimens, 
including long-term sustained NiAc exposures. Moreover, a different method 
for capturing tolerance was successfully incorporated into the pharmaco-
dynamic models giving the model the flexibility required to capture complete 
tolerance development. It is anticipated that this model will be helpful to 
further optimize NiAc dosing regimens. 
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6.6 Design aspects for durable NiAc-induced antilipolysis  
Therapeutically relevant NiAc exposures. The goal was to achieve a 
therapeutically relevant plasma NiAc concentration of ~1 µM, based on the 
concentration-response relationship for FFA lowering, delivering a close to 
maximal FFA suppression in substance naïve rats (Oakes et al., 2013; 
Ahlstrom et al., 2013). Data confirmed that this was the case. It is important to 
have a sufficient, but not excessive level of NiAc for two reasons. Firstly, loss 
of FFA lowering might theoretically be exacerbated by sustained supra-
maximally effective levels of target engagement, e.g. by ligand-induced 
GPR109A desensitization and internalization (Li et al., 2012). Secondly, 
excessive exposures can invoke additional complicating mechanisms beyond 
FFA lowering. Examples include: hepatic DGAT2 inhibition with an IC50 of 
100 µM (Blond et al., 2014; Ganji et al., 2004); suppression of glucose 
mediated insulin secretion via direct activation of GPR109A in the islet 
observed at 100 µM (Li et al., 2011; Chen et al., 2015); downregulation of 
PDE-3B in adipose tissue reported at ~10-fold higher dose of NiAc than used 
in the current study (Oh et al., 2011), but not occurring at the present dose 
level (Kroon et al., 2015); and finally Toll-like receptor-4 signaling inhibition 
observed at 100 µM (Digby JE et al., 2012). 
Limiting tolerance. The standard pharmacological approach of engaging the 
target mechanism (GPR109A activation) for 24 hr/day fails in the case of 
NiAc, as prolonged exposure induces tolerance development, with FFA 
returning to pretreatment levels (Oh et al., 2011). Therefore, intermittent 
dosing with 12 hr drug holidays were applied, resulting in containment, but not 
elimination of tolerance (Paper II). Thus, tolerance still developed when NiAc 
was applied in the fasting state; evident at the start of the experiment in the 
NiAc Day group (Paper III). Given the magnitude of tissue lipid unloading 
when NiAc was timed to feeding, extent of tolerance development was likely 
reduced in this group. 
Minimizing FFA rebound. It was hypothesized that the FFA rebound is 
potentiated by a rapid decline of NiAc exposure towards the FFA lowering 
potency (~0.07 µM). Therefore (in Paper III), an infusion protocol terminated 
by a gradual withdrawal was implemented. This protocol prolonged the fall of 
plasma NiAc concentrations to 0.07 µM by ~2 hr vs. abrupt NiAc infusion 
termination. Indeed, FFA rebound was minimized, when combined with 
glucose loading. In contrast, when NiAc was gradually withdrawn under 
fasting conditions, FFA exposure was actually increased vs. saline control. 
These results suggest that timing NiAc withdrawal to the fed state will 
maximize FFA lowering. A caveat, however, is that withdrawal under 
conditions of glucose loading, worsens glycemic control (Paper III). To 
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minimize the impact of this effect, withdrawal was timed to occur late in the 
feeding period. 
Timing NiAc administration to feeding. The potential for FFA lowering 
might in theory be greater in the fasting state. However, it has been suggested 
that antilipolysis in this situation (compared to the fed) may invoke a more 
powerful counterregulatory response to defend the supply of the predominant 
oxidative fuel (Guyton et al., 2015; Vega et al., 2005). Some evidence for this 
comes from a study in rats, where FFA was acutely lowered in the fasting state 
either by NiAc, an A1 adenosine receptor agonist or insulin in combination 
with glucose infusion to maintain euglycemia (Oh et al., 2012). Interestingly 
and in support of the above idea, increases of plasma adrenocorticotropic 
hormone (ACTH) and the lipolytic hormone corticosterone were attenuated 
with insulin/glucose (a situation somewhat akin to the fed state) compared to 
the other interventions. Another reason for applying NiAc during feeding is to 
exploit an insulin-NiAc synergy on antilipolysis. The clamp study results 
shows that insulin sensitization occurs when NiAc is present at sufficient levels 
for FFA lowering (Paper II). Based on the above factors, it is anticipated that 
NiAc application during the postprandial state would deliver greatest benefit to 
glucose and FFA control, which indeed is the case (Paper III). 
6.7 Experimental paradigm – key experimental design features 
Several features of the experimental design were key to being able to 
answer the principal questions of this work. 1) Properties of NiAc. Chemical 
stability, high potency against GPR109A and high solubility allow infusion 
solutions of sufficient concentration to achieve target plasma NiAc exposures 
over the 5 day period, in spite of the small depot volume in the implanted 
pump. A very short plasma half-life (~2 min in the rat) provides the freedom to 
design and realize almost any desired NiAc exposure profile. 2) Pro-
grammable, implantable pump. This device enables implementation of infusion 
protocols to reliably and precisely achieve the desired exposure profiles 
(shapes and timing) with a low degree of invasiveness. 3) Distinct feeding and 
fasting cycles. A fundamental aspect to the design in Paper III was to time 
NiAc to either the fasting or feeding periods. To ensure that this occurred, 
well-defined feeding/fasting periods were entrained in the hyper-phagic obese 
Zucker rats, by restricting food availability to the 12 hr dark period only. 
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6.8 Clinical implications for the use of niacin 
Could the present results have implications for the clinical use of niacin? 
Following the negative outcomes of two recent clinical trials (AIM-HIGH and 
HPS2-THRIVE (AIM-HIGH Investigators et al., 2011; HPS2-THRIVE 
Collaborative Group, 2013; HPS2-THRIVE Collaborative Group et al., 2014)) 
prescriptions have been declining (IMS Health Inc., ) and there is considerable 
debate about the value of niacin therapy (Guyton et al., 2013; Toth et al., 2015; 
Haynes & Rahimi, 2016). In addition, patient studies (with standard bedtime 
dosing) continue to report impairments in insulin sensitivity and/or glycemic 
control (Aye et al., 2014; Blond et al., 2014; Koh et al., 2014; Hu et al., 2015; 
Ooi et al., 2015; El Khoury et al., 2016) and even increased risk of new-onset 
diabetes (Goldie et al., 2016). Is it possible that the standard dosing regimen 
with extended release niacin (the predominant formulation), including bedtime 
administration, plays a role in limiting clinical efficacy and inducing negative 
glycemic effects? Indeed, mealtime dosing has been suggested as an approach 
to augment the clinical efficacy of this drug (Guyton et al., 2015; Usman MH 
et al., 2012). Extended release niacin given immediately before an oral fat 
tolerance test suppressed post-prandial FFA and plasma TG excursions (Usman 
MH et al., 2012). Consistent with the idea of mealtime over bedtime dosing, in 
Paper III, plasma TG lowering when treatment was timed to the OGTT and not 
when it was timed to fasting. Additionally, the results in Paper III suggest that 
mealtime dosing even has the potential to improve glycemic control. 
It should be pointed out, that the specific exposure profile of NiAc used in 
our preclinical studies markedly differs from exposures achieved following 
oral niacin dosing in patients (Kesisoglou F et al., 2014). An intermittent NiAc 
exposure profile equivalent to the ones used in the present studies, has to our 
knowledge not been applied in the clinic. This is important because different 
profiles may have different effects on average FFA levels. Several factors 
probably prevent present day ER formulations from reducing average FFA 
levels. 1) Dosing has not been designed to lower FFA, rather the goal has been 
to ameliorate dyslipidemia, via effects that may be independent of the FFA 
lowering mechanism (Lauring et al., 2012). 2) While the ER formulation 
prolongs plasma NiAc exposure, maximum plasma NiAc levels are reduced 
compared to equivalent crystalline formulation doses (Kesisoglou F et al., 
2014), likely resulting in poor FFA suppression over a large fraction of the day 
(based on the relationship between circulating NiAc levels and FFA 
suppression, (Carlson et al., 1968)). 3) In addition, clinical dosing is also 
associated with significant FFA rebound (Carlson & Oro, 1962; Lauring et 
al., 2012). Therefore, simply giving currently available formulations at meal-
time, may not reproduce the beneficial effects seen in Paper III. Nonetheless, 
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aside from timing, the data also indicate the importance of a prolonged drug 
washout to minimize the FFA rebound. In combination with mealtime dosing, 
prolonged drug washout might explain improvements in glucose control seen 
with acipimox (Vaag & Beck-Nielsen, 1992; Makimura et al., 2015) but not 
niacin (Grundy et al., 2002), given the longer plasma half-life of acipimox 
compared to niacin (Efthymiopoulos et al., 1993; Gugler, 1978).  
6.9 Implications for drug discovery 
The results within this thesis have important general implications for the phar-
macological approaches applied when assessing new modalities aimed to cure 
metabolic disease. The main project return deliveries, from a drug discovery 
perspective, are summarized in the bottom row of Table 1. In paper I, it was 
found that acute responses to NiAc differs substantially between lean and 
obese rats. Thus, in a preclinical drug discovery project, targeting a metabolic 
ailment, early screening of test compounds in a suitable disease animal model 
may be pivotal for sound conclusions and correct decision making. Although 
acute data is helpful and necessary to assess the proof of principle or target 
engagement, pharmacological intervention of metabolic pathways must include 
repeated dosing. When settling on level of exposures for repeated dosing in 
animals, it is often based on in vitro IC50/EC50 data, with the aim of achieving a 
specific fold above this in vitro potency. However, very little, if any, attention 
is given to various durations of daily exposures. In fact, it is often implied that 
drug coverage at this specific exposure is needed 24 hr/day for meaningful 
effects. Thus, based on the particular pharmacokinetic profile of the test com-
pound a dosing rate is then set to achieve level of target engagement, which 
often will involve multiple daily doses to ensure complete drug coverage. 
Paper II demonstrates that an around-the-clock exposure approach 
completely fails in the case of NiAc to deliver durable FFA lowering, due to 
comprehensive tolerance development. In contrast, drug efficacy is retained 
when hitting the target mechanism with therapeutically meaningful exposures 
for 12 hr/day. Although some loss of efficacy occurred between NiAc naïve 
and intermittently dosed obese animals (day 1 vs. 5), importantly, this did not 
appear to be progressive, with similar FFA lowering achieved day 5 vs. 11. 
Thus, in the case of durable NiAc-induced FFA lowering, interspacing daily 
exposures by drug holidays is essential for maintained drug efficacy. 
Paper III revealed that the details of the intermittent exposure profile 
(timing and shape) plays a critical role in metabolic outcomes. Thus, fine-
tuning of the intermittent exposure profile (shape) was needed in order to 
tackle the rebound phenomenon. This demonstrates the importance of careful 
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characterization of pharmacodynamic effects during washout. Specifically, 
effects stemming from exposures equivalent to predicted drug potency since 
rebound phenomena are most likely to be revealed at this level of exposures. 
Finding an optimal plasma half-life of a compound should thus not only be 
regarded as a means of establishing target exposures with minimal number of 
needed doses. The plasma half-life may also have significant impact on 
sustainable net effects, especially if rebound phenomena are involved. 
Metabolism is a tightly regulated processes and does not simply occur at 
random. Interfering with systems that are fundamental for organism survival, 
with millions of evolutionary years in development, is not trivial. Simply 
“plugging a leaking hole” often does not work in metabolism, especially not 
when trying to restrain or activate a metabolic pathway for 24 hr/day. The data 
from Paper III clearly demonstrate that also timing of target engagement with 
respect to normal physiological conditions, such as feeding, may be essential 
for improved metabolic control. Completely different responses occurred when 
a 12 hr time-shifted, but otherwise identical NiAc dosing regimen was applied 
in conjunction with feeding/fasting. Thus, attention should be given to timing 
of drug exposure and normal physiological conditions that might influence 
drug-induced effects. 
Modulation of a metabolic processes will undoubtedly result in buildup of 
pathway specific precursors or metabolites. Given the stringent regulation in 
normal metabolism, this buildup will likely activate backup pathways, cause 
cellular harm or trigger endogenous counterregulatory processes. Thus, 
duration, extent and timing of the target engagement mechanism may be of 
equal importance and crucial for successful discovery of new modalities acting 
on metabolic disease. 
6.10 Future perspectives 
Although repeated dosing was used in the present studies, ideally the 5-day 
treatment paradigm should be extended, in order to assess maintained efficacy 
and metabolic improvements. Given the relatively small depot volume for the 
dosing solution in the implantable pump, extending present protocols requires 
refills. Indeed, the pumps has this feature, however, it requires a percutaneous 
needle penetration for access to the refill septum situated on the pump. Thus, 
whether this could be done in the conscious state or requires anesthesia would 
need to be assessed. Given that anesthesia potentially disturbs metabolism, 
weekly refills with this approach may prove detrimental for improved 
metabolic control. The pump is also limited by its battery life. Thus, in obese 
rats the intermittent protocol with gradual washouts would use up the battery 
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after ~5 weeks and dosing solutions would need to be refilled several times. 
Although experimentally challenging, it can be done. Furthermore, in the 
present studies, tolerance development was contained but not fully 
circumvented. Thus, whether the intermittent dosing approach could be further 
optimized still needs to be explored. To this end, quantitative pharmacological 
approaches, using modeling should be used to predict both optimal exposure 
levels and durations, which would maximize FFA lowering and potentially 
further improve metabolic control. This exercise was indeed our intention with 
the development of the model in Paper IV. However, in the interest of time this 
activity did not make it into this thesis.     
Whether improvements in metabolic control, seen in the present studies are 
unique to NiAc needs to be explored. Furthermore, can the results be repeated 
in other preclinical disease models? For example, using other GPR109A 
agonists, with distinct molecular chemistry e.g. acipimox, could shed light on 
whether GPR109A agonism per se indeed produces similar effects. Another 
important question is whether antilipolysis via different targets, e.g. GPR81 or 
the A1 adenosine receptor, would result in similar effects. Again, this would be 
experimentally challenging but possible if drug candidates with adequate 
solubility, potency and pharmacokinetic properties could be identified. 
An intriguing and important question is whether similar effects could be 
achieved in humans. This would, however, not be a trivial, given the need for 
well controlled NiAc exposures and present available oral formulations. 
However, a short duration experiment using i.v. infusions would likely suffice 
as a proof of principle. 
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7 Conclusions 
The simple feedback turnover model adequately describes acute FFA responses 
to NiAc exposure and washout in metabolically healthy and diseased states. In 
obese animals, the model captures reduced efficacy, pronounced tolerance 
development and diminished rebound compared to lean animals at equivalent 
NiAc exposures. Importantly, the model aided in designing a gradual NiAc 
infusion termination protocol to minimize FFA rebound. The improved model 
is required for longer term experiments, capturing the development of complete 
tolerance in response to sustained NiAc exposure. An important endogenous 
regulator of lipolysis is insulin, which undergoes large dynamic changes in 
response to NiAc. The improved model therefore also incorporates the 
influence of insulin on FFA dynamics. It is anticipated that this model will be 
helpful to further optimize NiAc dosing regimens. 
A major finding is the substantial influence that the NiAc exposure profile 
has on metabolic control. The strategy of around-the-clock NiAc exposure fails 
to deliver durable FFA lowering due to tolerance development. By contrast, an 
intermittent NiAc dosing strategy succeeds in retaining FFA lowering and 
acute insulin sensitizing effects. However, this approach does not reverse lipid-
overload. This is achieved through a synergy between pharmacology and 
physiology by timing NiAc exposure to feeding periods which reverses 
peripheral lipid accumulation and profoundly improves lipid and glucose 
control. This thesis supports the concept that antilipolysis, applied in con-
junction with feeding, can be an effective means of reversing lipid overload-
induced insulin resistance and dyslipidemia. Pharmacological principles for 
treating metabolic disease may require careful fine-tuning (timing and shape) 
of drug exposures. 
In conclusion, a macro-pharmacologic approach can succeed in identifying 
a rational NiAc exposure that circumvents the problems of rebound and 
tolerance and profoundly improves metabolic control in a preclinical model of 
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the metabolic syndrome. The work shows the power of a multi-disciplinary 
drug discovery approach, using a comprehensive understanding of the relation-
ship between pharmacokinetics and pharmacodynamics combined with 
knowledge of the physiologic regulation of metabolism. 
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Populärvetenskaplig sammanfattning 
Sockersjuka (typ 2-diabetes) är en mycket alvarligt sjukdom som idag drabbar 
hundratals miljoner människor. Mycket tyder på att inlagring av fett i skelett-
muskulatur och lever, istället för i fettväv, är en grundläggande orsak till varför 
insulin förlorar sin effekt (s.k. insulinresistens); en starkt bidragande faktor för 
att utveckla typ 2-diabetes. Hos sjuka individer läcker det fett ifrån fettväven i 
form av fria fettsyror, och bidrar till fettinlagringen i muskel och lever. 
Nikotinsyra är ett läkemedel som ökar det goda och sänker det dåliga fettet i 
blodet och används för att minska risken för hjärtsjukdomar. På kort sikt kan 
nikotinsyra även sänka koncentrationen av fria fettsyror i blodet, genom att 
stänga av dess läckage från fettväven. För att uppnå en önskad effekt på längre 
sikt och på så vis kunna hjälpa patienter måste två problem lösas: om 
nikotinsyra ges oavbrutet tappar den sin effekt (toleransutveckling) och 
försvinner det ur kroppen för snabbt, sker en mycket hastig och kraftig ökning 
av fria fettsyror i blodet; ett fenomen som kallas för rebound. 
I denna avhandling undersöks idén att en mer omfattande förståelse av för-
hållandet mellan farmakokinetik (hur blodhalter av läkemedel ändras över tid) 
och farmakodynamik (vad läkemedel har för effekter) i kombination med 
kunskap om den normala regleringen av ämnesomsättningen (metabolismen), 
kan användas för att motverka tolerans och rebound och möjliggöra nya 
effektiva läkemedelsbehandlingar. Arbetet utfördes i en tvärvetenskaplig 
utvecklingsmiljö vid AstraZeneca R&D Gothenburg. Metabola konsekvenser 
av nikotinsyra-inducerad fettsyresänkning bedömdes i en experimentell 
modell, den feta Zucker-råttan, som har en rubbad ämnesomsättning mycket lik 
den hos typ 2-diabetiker. En högteknologisk programmerbar mini-pump var 
kirurgiskt inopererad och möjliggjorde för skräddarsydda doseringsprofiler och 
fullständig kontroll över blodkoncentrationen av nikotinsyra. Genom att lägga 
in resultaten i matematiska modeller kunde effekter från olika typer av 
doseringar förutsägas och användas för att förbättra doseringsprofilen. En 
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enkel modell fungerade bra för korta behandlings perioder medan en mer 
komplex modell behövdes för långvarig behandling. 
Detta avhandlingsarbete visar på det stora inflytande som doseringsprofilen 
av nikotinsyra har på metabol kontroll. När koncentrationen av nikotinsyra 
hölls konstant, dygnet runt, skedde en fullständig återgång av fettsyrorna till 
ursprungsnivån, på grund av toleransutveckling. Vid en intermittent doserings-
strategi, när nikotinsyra tillfördes 12 timmar per dag, kvarstod en fettsyre-
sänkande effekt, samt en förbättrad insulinkänslighet. För att uppnå en bestå-
ende effekt, kraftfull nog för att minska fettinlagring i muskel och lever, 
krävdes en samverkan mellan farmakologi och fysiologi. Genom att låta ett 
optimerat doseringsprotokoll sammanfalla med födointag, istället för fasta, 
upptäcktes en kraftigt reducerad fettinlagring i lever, samt en markant för-
bättrad metabol kontroll. Denna avhandling stödjer grundtanken om att 
farmakologiskt inducerad fettsyresänkning i samband med föda, kan vara ett 
effektivt sätt att reducera fettinlagring i vävnader med en ökad effekt av insulin 
och förbättrad ämnesomsättning. 
Sammanfattningsvis har vi, i en djurexperimentell modell av metabol 
sjukdom, identifierat en doseringsprofil för nikotinsyra, och när det bör ges, 
som motverkar problemen med toleransutveckling och rebound och avsevärt 
förbättrar ämnesomsättningen. Arbetet visar på kraften hos ett tvärveten-
skapligt tillvägagångssätt i en läkemedelsutvecklingsmiljö applicerat på en 
omfattande förståelse kring förhållandet mellan farmakokinetik och farmako-
dynamik i kombination med kunskap om den fysiologiska regleringen av 
ämnesomsättningen. 
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